

BMJ Open

Incidence of diabetes-related complications in ethnic Chinese with newly diagnosed type 1 diabetes, 1999-2013

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015117
Article Type:	Research
Date Submitted by the Author:	09-Nov-2016
Complete List of Authors:	Ou, Huang-tz; National Cheng Kung University College of Medicine, Institute of Clinical Pharmacy and Pharmaceutical Sciences ; National Cheng Kung University College of Medicine, Pharmacy Lee, Tsung-Ying ; National Cheng Kung University College of Medicine, Institute of Clinical Pharmacy and Pharmaceutical Sciences Li, Chung-Yi; National Cheng Kung University College of Medicine, Public Health; China Medical University, Public Health Wu, Jin Shang ; National Cheng Kung University College of Medicine, Family Medicine; National Cheng Kung University Hospital, Family Medicine Sun, Zih Jie ; National Cheng Kung University Hospital, Family Medicine; National Cheng Kung University Hospital Dou-Liou Branch, Family Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Health services research
Keywords:	DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Diabetic neuropathy < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Incidence of diabetes-related complications in ethnic Chinese with newly diagnosed type**
4 **1 diabetes, 1999-2013**
5

6
7
8 Huang-Tz Ou PhD^{1,2,*}, Tsung-Ying Lee MS¹, Chung-Yi Li PhD^{3,4}, Jin-Shang Wu MD^{5,6},
9 Zih-Jie Sun MD^{6,7}
10

11
12 ¹Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National
13 Cheng Kung University, Tainan, Taiwan

14
15 ²Department of Pharmacy, College of Medicine, National Cheng Kung University Tainan,
16 Taiwan

17
18 ³Department of Public Health, College of Medicine, National Cheng Kung University, Tainan,
19 Taiwan

20
21 ⁴Department of Public Health, China Medical University, Taichung, Taiwan

22
23 ⁵Department of Family Medicine, College of Medicine, National Cheng Kung University,
24 Tainan, Taiwan

25
26 ⁶Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan

27
28 ⁷Department of Family Medicine, National Cheng Kung University Hospital, Dou-Liou
29 Branch, Dou-Liou, Taiwan
30

31
32
33
34
35
36 ****Corresponding author***

37 Huang-Tz Ou, PhD

38
39 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National
40 Cheng Kung University,

41
42 1 University Road, Tainan 7010, Taiwan

43
44 Phone: +886-6-2353535 ext.5685

45
46 Fax: +886-6-2373149

47
48 Email: huangtz@mail.ncku.edu.tw
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To estimate the incidence densities and cumulative incidence of diabetes-related complications in patients with type 1 diabetes for a maximum of 15-year follow-up. The estimations were further stratified by gender and age at diagnosis (i.e., early-onset: 0-12 years, late-onset: ≤ 13 years).

Design: A population-based longitudinal cohort study.

Setting: Taiwan's National Health Insurance medical claims.

Participants: 4,007 patients newly-diagnosed with type 1 diabetes were identified during 1999-2012.

Outcome measures: Acute complications included diabetic ketoacidosis (DKA) and hypoglycemia. Chronic complications were cardiovascular diseases (CVD), retinopathy, neuropathy, and nephropathy.

Results: The incidence density of retinopathy was greatest (97.74 per 1,000 person-years), followed by those of nephropathy (31.36), neuropathy (23.93), and CVD (4.39). Among acute complications, the incidence density of DKA was greatest (121.11 per 1,000 person-years). The cumulative incidences of acute complications after 12 years following diagnosis were estimated to be 52.1%, 36.1%, and 4.1% for DKA, mild hypoglycemia, and

1
2
3
4 hospitalized hypoglycemia, respectively. For chronic complications, the cumulative incidence
5
6
7 of retinopathy after 12 years following diagnosis was greatest (65.2%), followed by those of
8
9
10 nephropathy (30.2%), neuropathy (23.7%), and CVD (4.1%). Females with late-onset
11
12
13 diabetes were greatly affected by advanced retinopathy (i.e., sight-threatening diabetic
14
15
16 retinopathy) and hospitalized hypoglycemia, whereas those with early-onset diabetes were
17
18
19 more vulnerable to DKA. Chronic complications were more commonly seen in late-onset
20
21
22 diabetes, whereas early-onset diabetes were most affected by acute complications.
23

24
25 **Conclusions:** Ethnically Chinese patients with type 1 diabetes were greatly affected by DKA
26
27
28 and retinopathy. Significant age-sex disparities in the incidence of diabetes-related
29
30
31 complications affect such individuals.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- ✓ This is the largest longitudinal cohort study of ethnically Chinese patients with type 1 diabetes followed for a maximum of 15 years to provide up-to-date incidence estimates of acute and chronic complications.
- ✓ The analyses stratified by gender and age at diabetes-onset indicated significant age-gender disparities in the epidemiological data of diabetes-related complications in type 1 diabetes, which highlight importance for clinical attention and developing preventive strategies.
- ✓ The study limitations resulting from the use of medical reimbursement claims data, including potential misclassifications of diabetes-related complications and lack of clinical biomarkers such as blood glucose, may underestimate rather than overestimate the incidence rates of diabetes-related complications.
- ✓ The incidence estimates of diabetes-related complications may only be generalizable to ethnically Chinese population with type 1 diabetes.

Introduction

It has been estimated that the incidence of type 1 diabetes increases by about 3-5% per year worldwide.¹⁻³ The annual incidence rate of childhood (< 15 years) type 1 diabetes in Taiwan was 5.3 per 100,000 children in the period 2003-2008.⁴ Type 1 diabetes accounts for only 5-10% of the diabetic population, but it remains a devastating chronic disorder with acute complications, including diabetic ketoacidosis (DKA) and hypoglycemia, and chronic complications, which can be divided into microvascular (i.e., retinopathy, neuropathy, nephropathy) and macrovascular complications (i.e., cardiovascular diseases; CVD). Although treatment and care for type 1 diabetes have improved,⁵⁻⁷ diabetes-related complications are major obstacles to glycemic control for many patients and contribute to most of the increased morbidity and premature mortality in such individuals.⁸ The toxicity effect of prolonged chronic hyperglycemia is a leading cause of microvascular and macrovascular diseases among type 1 diabetes patients, with hypertension and dyslipidemia being exacerbating factors.⁹

Assessing the epidemiology of diabetes-related complications is essential for developing preventive strategies and planning treatment protocols to minimize the impact of the complications. However, there is very little longitudinal data (e.g., Pittsburgh Epidemiology

1
2
3
4 of Childhood-Onset Diabetes Complications (EDC) Study,¹⁰ EURODIAB IDDM
5
6
7 Complications Study¹¹) on the incidence of complications for type 1 diabetes, and previous
8
9
10 estimates widely vary by country and follow-up period (e.g., 7 years,¹² 12 years,¹³ 18 years,¹⁴
11
12
13 30 years¹⁰). In addition, a limited number of diabetes-related complications have been
14
15
16 investigated (e.g., microalbuminuria^{12, 14} and cardiovascular diseases; CVD¹³), with no
17
18
19 previous study targeting an ethnic Chinese population with type 1 diabetes. Ethnic variations
20
21
22 in diabetes-related complications have been recognized; Caucasian patients are greatly
23
24
25 affected by CVD,^{15, 16} while the prevalence of end-stage renal failure (ESRD)¹⁷ and the odds
26
27
28 of microalbuminuria and macroalbuminuria¹⁸ in Asian populations are much higher compared
29
30
31 to those for Caucasian patients. Given the significance of rising life expectancy in recent
32
33
34 years among ethnic Chinese patients with type 1 diabetes,¹⁹ it is important to provide precise
35
36
37 up-to-date estimates of incidence of its complications and compare them to those for other
38
39
40 countries. We therefore utilized a longitudinal population-based cohort of newly diagnosed
41
42
43 type 1 diabetes patients who were followed during the period 1999-2013 to evaluate the
44
45
46 incidence densities and cumulative incidences of acute and chronic complications to provide
47
48
49 contemporary estimates for an ethnic Chinese population. Efforts were also made to examine
50
51
52 whether there were age and sex differences in the incidences of type-1-diabetes-related
53
54
55
56
57
58
59
60

1
2
3
4 complications.
5
6
7
8
9

10 **Materials and Methods**

11
12
13 The Institutional Review Board of National Cheng Kung University Hospital approved
14
15
16 the study before commencement (A-ER-103-298).
17

18 Data source:

19
20
21
22 We utilized the Longitudinal Cohort of Diabetes Patients (LHDB) 1996-2013 data from
23
24
25 the National Health Insurance Research Database (NHIRD). Taiwan's NHIRD is
26
27
28 population-based and derived from the claims data of the National Health Insurance (NHI)
29
30
31 program, a mandatory-enrollment, single-payment system that covers over 99% of Taiwan's
32
33
34 population.²⁰ The LHDB is a valid national dataset that consists of a random sample of
35
36
37
38 120,000 de-identified diabetes incident cases from each calendar year, who were tracked back
39
40
41 to 1996 and followed up to 2013 to establish a longitudinal cohort. The LHDB is
42
43
44 representative of Taiwan's population with diabetes and provides research opportunity to
45
46
47 evaluate long-term health outcomes of patients.
48

49 Cohort:

50
51
52
53 From the LHDB, we selected 4,677 patients with a diagnosis of type 1 diabetes
54
55
56

1
2
3
4 (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM =
5
6
7 250.x1 or 250.x3) from outpatient files of the LHDB and having received a Catastrophic
8
9
10 Illness Card (CIC) for type 1 diabetes (Figure 1) in the period 1999-2012. Because patients
11
12
13 with a CIC are eligible for exemption from insurance premiums and co-payments, the
14
15
16 approval of such a status is subject to evaluation and review by the Bureau of NHI of Taiwan.
17
18
19 The CIC patient data are accurate and reliable with a positive predictive value of 98.3% for
20
21
22 type 1 diabetes.¹⁹ We further excluded 670 potential type 2 diabetes cases who consumed any
23
24
25 oral antihypoglycemic agents (OHAs) after CIC was issued, including sulfonylureas,
26
27
28 meglitinides, acarbose, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide-1
29
30
31 receptor agonists, and however, those who used metformin alone, thiazolidinediones alone, or
32
33
34 both were retained. Patients who were prescribed metformin, thiazolidinediones, or both were
35
36
37 retained because these OHAs are insulin-sensitizers that can be combined with insulin
38
39
40 treatments for cases with insulin resistance,^{21,22} which is also seen in patients with type 1
41
42
43 diabetes in Taiwan based on our expert opinions. To estimate the incidence rates of
44
45
46 diabetes-related complications, we further selected cases without a history of microvascular
47
48
49 or macrovascular diseases before type 1 diabetes diagnosis (Table 1). Study patients were
50
51
52 stratified by gender and age at first type 1 diabetes diagnosis (i.e., early-onset: 0-12 years,
53
54
55
56
57
58
59
60

1
2
3
4 late-onset: ≤ 13 years).
5
6

7 Diabetes-related complications:
8
9

10 The complications of interest included acute complications, namely DKA (confirmed by
11
12 hospital admission or emergency room visit for DKA), mild hypoglycemia (confirmed by
13
14 outpatient visit for hypoglycemia), and hospitalized hypoglycemia, and chronic
15
16 complications, namely CVD, nephropathy, retinopathy, and neuropathy. A list of
17
18 diabetes-related complications and the corresponding ICD-9-CM codes are provided in
19
20 Supplementary Table 1; this list was confirmed by the expert panel before being applied.
21
22
23
24
25
26
27

28
29 Statistics:
30
31

32 The incidence density of diabetes-related complications was calculated by dividing the
33
34 number of incident cases with individual complication events by the total person-years
35
36 observed over 15 years of follow-up (1999-2013). The 95% confidence intervals (CIs) were
37
38 calculated assuming a Poisson distribution of cases.²³ Because a cohort of newly diagnosed
39
40 type 1 diabetes patients was utilized, we were able to provide visual illustrations about the
41
42 cumulative incidences of diabetes-related complications by diabetes duration since diabetes
43
44 onset. The cumulative incidence of diabetes-related complications was estimated by using the
45
46 life table method (using the SAS LIFETEST procedure). Significant differences in incidence
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 density between age-sex subgroups were indicated by a 95% CI for the difference in
5
6
7 incidence density between subgroups.²⁴ SAS version 9.4 (SAS Institute Inc., Cary, NC) was
8
9
10 used for the aforementioned analyses.

16 **Results**

19 The overall and age-sex specific incidence densities of diabetes-related complications
20
21 are presented in Tables 1 and 2, respectively. The incidence rate of retinopathy (97.74 per
22
23 1,000 person-years) was greatest, followed by those of nephropathy (31.36), neuropathy
24
25 (23.93), and CVD (4.39). Among acute complications, the incidence density of DKA was
26
27 greatest (121.11 per 1,000 person-years). As shown in Table 2, the incidence densities of
28
29 retinopathy, DKA, and hospitalized hypoglycemia in females were significantly higher than
30
31 those in males. The incidence densities of DKA and mild hypoglycemia in the early-onset
32
33 group (0-12 years) were significantly higher than those noted in the late-onset group (≤ 13
34
35 years), while those of advanced retinopathy (i.e., sight-threatening diabetic retinopathy;
36
37 STDR), neuropathy, nephropathy, CVD, and hospitalized hypoglycemia in the late-onset
38
39 group were significantly higher. Figures 2 and 3 show cumulative incidences for acute and
40
41 chronic complications, respectively, along with diabetes duration. The cumulative incidences
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 at the 12th year after diagnosis were 52.1%, 36.1%, and 4.1% for DKA, mild hypoglycemia,
5
6
7 and hospitalized hypoglycemia, respectively. For chronic complications, the 12-year
8
9
10 cumulative incidence of retinopathy was greatest (65.2%), followed by those of nephropathy
11
12
13 (30.2%), neuropathy (23.7%), and CVD (5.2%). At 5 years after diabetes diagnosis, around
14
15
16 45% of patients experienced hypoglycemia, while at 10 years after diagnosis, about half of
17
18
19 patients had hypoglycemia. Age-sex specific cumulative incidences of diabetes-related
20
21
22 complications are illustrated in Supplementary Figure 1.
23
24
25
26
27
28

29 **Discussion**

30
31
32 To the best of our knowledge, this is the largest cohort study of ethnically Chinese
33
34
35 patients with newly diagnosed type 1 diabetes. We provided up-to-date estimates of the
36
37
38 incidence of acute and chronic complications in type 1 diabetes patients followed for a
39
40
41 maximum of 15 years. We observed age-gender disparities in the incidence of
42
43
44 diabetes-related complications in type 1 diabetes. Although comparisons of the epidemiology
45
46
47 of diabetes-related complications between studies are difficult, as potential determinants of
48
49
50 the complications (e.g., age, gender, diabetes duration) differ, the estimates from different
51
52
53 studies may reveal some racial or ethnic differences. In the following, we compare our results
54
55
56
57
58
59
60

1
2
3
4 for ethnically Chinese patients with those reported for other countries or ethnicities.
5
6

7 **Acute diabetes-related complications in type 1 diabetes patients**

8
9

10 *Diabetic ketoacidosis*

11
12

13 Among acute complications, hyperglycemic events, including DKA and hyperglycemic
14
15
16 hyperosmolar syndrome (HHS), are leading causes of morbidity and mortality among
17
18
19 individuals with diabetes,²⁵ and utilize significant healthcare resources.²⁶ DKA was the most
20
21
22 common acute complication among the Taiwanese population with type 1 diabetes; the
23
24
25 incidence density followed for 15 years was 121.11 per 1,000 person-years, and half of the
26
27
28 study population (~52%) experienced DKA at 12 years after diabetes diagnosis. Consistent
29
30
31 with previous studies from the United States,²⁷ Australia,²⁸ and Canada,²⁹ we found that the
32
33
34 incidence of DKA in female patients, especially those with early-onset diabetes (i.e., 0-12
35
36
37 years), was higher than that in male patients. A cohort of 1,234 children with type 1 diabetes
38
39
40 in the United States showed that female patients were greatly affected by DKA. A female
41
42
43 preponderance of DKA was observed in a longitudinal study of childhood type 1 diabetes in
44
45
46 Australia.²⁸ Similarly, a Canadian study of childhood type 1 diabetes showed that female sex
47
48
49 was a significant predictor of DKA.²⁹ In fact, insulin omission or intentional insulin
50
51
52 under-treatment due to fear of weight gain³⁰ and high prevalence of eating disorders³¹ and
53
54
55
56
57
58
59
60

1
2
3
4 psychiatric disorders²⁷ among female type 1 diabetes patients have been recognized as
5
6
7 precipitating causes of DKA. Hence, effective interventions such as health education and
8
9
10 communication for type 1 diabetes females are needed to reduce the incidence of DKA.
11

12 13 *Hypoglycemia*

14
15
16 Increased hypoglycemic events have been recognized as a result of the undesired effects
17
18
19 of intensive insulin therapy with strict glycaemic control.³² The present study showed that the
20
21
22 incidence rates of hospitalized and mild hypoglycemia in the Taiwanese population with type
23
24
25 1 diabetes were 3.89 and 39.93 per 1,000 person-years, respectively, which are much lower
26
27
28 than that reported in type 1 diabetes children (0-19 years) in the United States (incidence of
29
30
31 severe hypoglycemia: 190 per 1,000 person-years).²⁷ Such discrepancies in international data
32
33
34 may be explained by different definitions and assessment approaches for hypoglycemic
35
36
37 events. We targeted hospital admissions for severe hypoglycemia based on ICD-9 CM codes,
38
39
40 whereas the United States study used patients' reported survey data and classified severe
41
42
43 hypoglycemia as acute episodes requiring the assistance of another person for treatment
44
45
46 reported in the preceding 3 months.³³
47
48
49

50
51 Moreover, we observed that early-onset patients were greatly affected by acute
52
53
54 complications (i.e., DKA, hypoglycemia). It has been documented that among young children
55
56

1
2
3
4 with type 1 diabetes, inconsistent eating patterns and lesser ability to recognize and report
5
6
7 acute symptoms make it difficult to achieve glycaemic control, leading to glycaemic
8
9
10 fluctuations that cause multiple episodes of hyperglycaemia (i.e., DKA) and hypoglycaemia.³⁴
11
12
13 Frequent exposures to hyperglycaemia and hypoglycaemia in early-onset type 1 diabetes
14
15
16 patients could lead to a range of neurocognitive dysfunctions and brain changes.³⁵ Also,
17
18
19 structural brain changes in type 1 diabetes children may occur due to recurrent
20
21
22 hypoglycaemia.³⁶ Hence, given the high rates of acute complications and associated serious
23
24
25 consequences, effective management protocols and identification and treatment of
26
27
28 precipitating causes are needed.³⁷ In particular, regular glycaemic monitoring and
29
30
31 identification of risk factors in young type 1 diabetes patients are needed to reduce the
32
33
34 frequency and severity of DKA and hypoglycaemia.
35
36

37 38 **Chronic diabetes-related complications in type 1 diabetes**

39 40 41 *Diabetic retinopathy*

42
43
44 Diabetic retinopathy is the main cause of blindness in the adult population.³⁸ Almost all
45
46
47 type 1 diabetes patients develop evident retinopathy in the first 20 years of diagnosis.³⁹ The
48
49
50 present study showed that more than half (~69%) of type 1 diabetes patients experienced
51
52
53 some form of diabetic retinopathy at 12 years after diagnosis. We observed that the incidence
54
55
56

1
2
3
4 density of diabetes retinopathy is greatest among chronic complications in Taiwanese type 1
5
6
7 diabetes patients (4.53 per 100 person-years over a period of 15 years of follow-up). As
8
9
10 compared to the incident density of proliferative retinopathy (19.5 per 1,000 person-years) in
11
12
13 the Pittsburgh EDC Study of type 1 diabetes patients with a mean age of 28 years and
14
15
16 diabetes duration of 19 years at baseline examination,¹⁰ our estimate (5.87 per 1,000
17
18
19 person-year) based on a cohort of newly diagnosed type 1 diabetes patients is lower. Such a
20
21
22 difference between studies may be explained by diabetes duration and age at baseline of
23
24
25 study examination. Moreover, comparing the prevalence of STDR in type 1 diabetes patients
26
27
28 in this study (2.00 % for women and 1.66 % for men) with that previously observed in
29
30
31 Taiwanese type 2 diabetes patients (2.75% for women and 2.87% for men)⁴⁰ reveals a slightly
32
33
34 lower advanced diabetic retinopathy (i.e., STDR) in the type 1 diabetes versus type 2 diabetes
35
36
37 patients. However, the lower rate of STDR in our study may be due to the other study's
38
39
40 inclusion of prevalent type 2 diabetes cases with longer diabetes duration⁴⁰ as compared to
41
42
43 incident type 1 diabetes targeted in this study.
44
45

46
47 Consistent with previous studies,^{41, 42} the present study demonstrated a female
48
49
50 preponderance in diabetic retinopathy. A large cohort of 8,114 type 1 diabetes patients and
51
52
53 families assembled over 25 years from the United States showed that females had 1.7 fold
54
55
56

1
2
3
4 higher retinopathy risk ($p < 0.001$) as compared to that of males.⁴¹ Also, a cross-sectional
5
6
7 study of 247 Italian type 1 diabetes patients showed a significant relationship between
8
9
10 diabetic retinopathy and female gender ($p = 0.01$).⁴² Although exact hormone, genetic,
11
12
13 lifestyle, or environmental factors are unclear, a differential effect of sex steroid hormones
14
15
16 has been proposed to explain this gender discrepancy.⁴³ Also, age at diabetes onset has been
17
18
19 shown to be associated with the development of diabetic retinopathy.^{42, 44} An early age at
20
21
22 onset (5-14 years) appears to modify the long-term risk of proliferative retinopathy.⁴⁴
23
24
25 Consistent with other studies, we observed lower incidence of diabetic retinopathy in
26
27
28 early-onset patients as compared to that in late-onset patients. Nevertheless, given a high rate
29
30
31 of diabetes retinopathy observed among Taiwanese type 1 diabetes patients, early detection
32
33
34 using routine eye examination, control for risk factors of diabetic retinopathy (e.g.,
35
36
37 hypertension, hyperglycemia, hyperlipidemia),⁹ as well as development of tailored
38
39
40 intervention strategies for age-sex subgroups are important.
41
42
43

44 *Diabetic nephropathy*

45
46
47 Our results show that diabetic nephropathy is the second most common microvascular
48
49
50 complication among the Taiwanese population with type 1 diabetes. Without interventions,
51
52
53
54 diabetes patients with microalbuminuria typically progress to proteinuria and overt diabetic
55
56
57

1
2
3
4 nephropathy.⁴⁵ Diabetic nephropathy is a leading cause of ESRD among patients with
5
6
7 diabetes.⁴⁵ As estimated, individuals with type 1 diabetes face a 20-50% chance of
8
9
10 developing ESDR that requires dialysis or renal transplantation.⁴⁶ The Pittsburgh EDC Study
11
12
13 reported that the incidence density of renal failure (based on self-reported renal
14
15
16 transplantation and dialysis) was 6.3 per 1,000 person-years over 12 years of follow-up,¹⁰
17
18
19 while the present study based on ICD-9 codes of renal failure found that the incidence of
20
21
22 renal failure was 1.31 per 1,000 person-years over 15 years of follow-up. Of note, the EDC
23
24
25 study enrolled more advanced type 1 diabetes cases (i.e., mean age of 28 years and diabetes
26
27
28 duration of 19 years at baseline examination¹⁰) than those in our study (i.e., newly diagnosed
29
30
31 type 1 diabetes cases in 2000-2012), which may explain the higher rate of renal failure in the
32
33
34 EDC study. A large inception cohort study of Danish patients newly diagnosed with type 1
35
36
37 diabetes followed for a median of 18 years reported that the cumulative incidences of
38
39
40 persistent microalbuminuria and macroalbuminuria were 33.6% and 14.6%, respectively,
41
42
43 while the present study found that overall cumulative incidence of any form of diabetic
44
45
46 nephropathy was 30.2% at 12 years after diabetes diagnosis. Moreover, early-onset diabetes
47
48
49 appears to be protective for developing diabetic nephropathy^{12, 47-49} and may delay the time
50
51
52 until microalbuminuria.⁴⁹ Consistently, we found that late-onset diabetes patients were more
53
54
55
56
57
58
59
60

1
2
3
4 affected by diabetic nephropathy than were early-onset patients. Nevertheless, given the fact
5
6
7 that Taiwan has the highest number of patients undergoing renal dialysis in the world, where
8
9
10 diabetes contributes to about 40 % of end-stage renal failure cases,⁵⁰ it is critical for routine
11
12
13 annual screening of clinical signs of diabetic nephropathy (i.e., proteinuria,
14
15
16 microalbuminuria), optimal control of glycemia and risk factors (e.g., retinopathy smoking,
17
18
19 dyslipidemia, hypertension^{14, 51, 52}), and early intervening medications for prevention (e.g.,
20
21
22 angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for those with
23
24
25 comorbid hypertension).⁹

26 27 28 29 *Diabetic neuropathy*

30
31
32 Diabetic neuropathy refers to the presence of symptoms, signs, or both of peripheral
33
34
35 nerve dysfunction in people with diabetes after the exclusion of other causes.⁵³ Peripheral
36
37
38 neuropathy in diabetes may manifest in several different forms, including sensory,
39
40
41 focal/multifocal, and autonomic neuropathies.⁵⁴ The epidemiological data of diabetic
42
43
44 neuropathy is very limited. A study of 467 Italian type 1 diabetes patients showed that the
45
46
47 prevalence rates of asymptomatic and symptomatic neuropathy were 7.2% and 21.3%,
48
49
50 respectively.⁵⁵ The present study is the first study to provide epidemiology data on diabetic
51
52
53
54 neuropathy among ethnically Chinese patients with type 1 diabetes from Asia. We found that

1
2
3
4 the incidence rate was 23.93 per 1,000 person-years over 15 years of follow-up, and that the
5
6
7 cumulative incidence was 23.7% at 12 years after diabetes diagnosis. We also observed that
8
9
10 the incidence of diabetic neuropathy in late-onset patients were much higher than that in
11
12
13 early-onset patients. Similarly, the Italian study of type 1 diabetes showed that the prevalence
14
15
16 of diabetic neuropathy was higher in patients at older ages.⁵⁵ Since diabetic neuropathy
17
18
19 contributes to considerable disabilities and mortality, it is critical for clinicians to understand
20
21
22 its manifestations, prevention, and treatment.⁹ Early prevention strategies that control
23
24
25 hypertension and hyperglycemia and identify patients with peripheral neuropathy or
26
27
28 peripheral vascular disease and annual screening for these conditions are strongly
29
30
31 recommended.⁹
32
33

34 35 *Cardiovascular diseases*

36
37
38 CVD is a leading cause of mortality in patients with type 1 diabetes^{56,57} and accounts for
39
40
41 the greatest proportion of healthcare spending for patients with diabetes.^{57,58} As compared to
42
43
44 patients without diabetes, type 1 diabetes increases the risk of CVD by ten fold,^{56,59} which
45
46
47 contributes to two-thirds of mortality in patients with type 1 diabetes.^{60,61} The Pittsburgh
48
49
50 EDC Study showed an incidence density of 3.6 per 1,000 person-years for coronary heart
51
52
53 diseases (defined as coronary-artery-disease-related death, a history of myocardial infarction,
54
55
56
57
58
59
60

1
2
3
4 angiographic stenosis $\geq 50\%$ including revascularization) over a period of 12 years,¹⁰ while
5
6
7 the present study found that the incidence density for a broader category of CVD (including
8
9
10 myocardial infarction, ischemic heart diseases, heart failure, stroke, and arrhythmia, as shown
11
12
13 in Supplementary Table 1) in the Taiwanese population with type 1 diabetes within 15 years
14
15
16 of follow-up was 4.39 per 1,000 person-years. The cumulative incidences of CVD (including
17
18
19 only stroke and coronary heart disease) at 12 years after diabetes was diagnosed was 1-2%
20
21
22 among Finnish type 1 diabetes patients,¹³ which is lower than that for the Taiwanese type 1
23
24
25 diabetes patients in the present study (~5.2%). Moreover, we found that late-onset patients
26
27
28 were greatly affected by CVD. In fact, old age is recognized as a predictor of vascular
29
30
31 diseases,⁵⁶ which may be explained by the calcification of extremity arteries and hypertension
32
33
34 in older age patients, which are risk factors of macrovascular diseases.⁶²
35
36
37

38 **Methodological concerns**

39
40
41 Some limitations of this study should be acknowledged. The classification of
42
43
44 diabetes-related complications based on the ICD-9 CM codes in claims data may
45
46
47 underestimate the occurrence of the complications. For example, patients experiencing
48
49
50 clinical symptoms/signs of diabetes-related complications (e.g., hypoglycemia) may not see
51
52
53 doctors if they can tolerate them. Also, the claims data do not capture clinical/minor
54
55
56
57
58
59
60

1
2
3
4 symptoms or signs of diabetes-related complications such as minor microalbuminuria. The
5
6
7 glycemic biomarkers such as blood glucose were not available from the claims data so the
8
9
10 identification of hyperglycemia or hypoglycemia was only based on the ICD-9 CM diagnosis
11
12
13 codes. However, the claims records capture defined diabetes-related complications that are
14
15
16 required for medical assistance or treatments, which lead to more conservative estimates and
17
18
19 reveal important manifestations of diabetes-related complications for clinical attention. Lastly,
20
21
22 the generalizability of our study results may be limited to ethnically Chinese populations. In
23
24
25 addition, our results may represent only ethnically Chinese patients with type 1 diabetes in
26
27
28 Taiwan.

31 **Conclusions**

32
33
34 Utilizing an incident cohort of type 1 diabetes patients diagnosed during the period
35
36
37 1999-2012 with a maximum of 15 years of follow-up, we found that most type 1 diabetes
38
39
40 patients were affected by DKA and retinopathy, which highlight the critical need to identify
41
42
43 precipitating causes and modifiable factors for developing preventive strategies and
44
45
46 intervening treatment protocols to minimize the impact of these complications. Age and sex
47
48
49 discrepancies appear in epidemiological data of diabetes-related complications; late-onset
50
51
52 diabetes females were greatly affected by advanced retinopathy (i.e., STDR) and hospitalized
53
54
55
56
57
58
59
60

1
2
3
4 hypoglycemia, while early-onset females had a high incidence of DKA. Chronic
5
6
7 diabetes-related complications were more common in late-onset type 1 diabetes patients,
8
9
10 while early-onset individuals were most affected by acute complications. More attention
11
12
13 should be given to identify potential risk factors and contributors to such age-sex differences
14
15
16 in diabetes-related complications. Population-based data on the incidence of diabetes-related
17
18
19 complications from this study are important for clinicians to recognize the need for diagnostic
20
21
22 awareness and for policy-makers to develop effective treatments for patients with type 1
23
24
25
26 diabetes.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Acknowledgments:** We gratefully thank National Cheng Kung University and its affiliated
5
6
7 hospital for all their support.
8
9

10
11
12
13 **Funding:** This research was supported by the Ministry of Science and Technology, Taiwan,
14
15
16 grant MOST 104-2320-B-006-008-MY3.
17
18

19
20
21
22 **Competing interests:** No declared.
23
24
25

26
27
28 **Authors' contribution:** H.T.O. contributed substantially to the study concept and design,
29
30 acquisition of data, analysis and interpretation of data. T.Y.L. contributed to data collection
31
32 and the analysis. C.Y.L., J.S.W., and Z.J.S. provided statistical and clinical interpretation of
33
34 the results. H.T.O. wrote the first draft of the manuscript, and T.Y.L., C.Y.L., J.S.W., and
35
36 Z.J.S. very critically revised the manuscript. All authors gave approval for the publication of
37
38 the final version.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of Type I diabetes—the analysis of the data on published incidence trends. *Diabetologia* 1999;42(12):1395-1403.
2. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. *Diabetes care* 2000;23(10):1516-1526.
3. Soltesz G, Patterson CC, Dahlquist G. Worldwide childhood type 1 diabetes incidence—what can we learn from epidemiology? *Pediatric diabetes* 2007;8(s6):6-14.
4. Lu CL, Shen HN, Chen HF, Li CY. Epidemiology of childhood Type 1 diabetes in Taiwan, 2003 to 2008. *Diabetic Medicine* 2014;31(6):666-673.
5. Goldstein DE, Walker B, Rawlings SS, Hess RL, England JD, Peth SB, Hewett JE. Hemoglobin A1c levels in children and adolescents with diabetes mellitus. *Diabetes Care* 1980;3(4):503-507.
6. Ziegler R, Heidtmann B, Hilgard D, Hofer S, Rosenbauer J, Holl R. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. *Pediatric diabetes* 2011;12(1):11-17.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *New England Journal of Medicine* 1993;329(20):1456-1462.
8. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-Cause Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 Diabetes The Allegheny County Type 1 Diabetes Registry. *Diabetes care* 2010;33(12):2573-2579.
9. Bate KL, Jerums G. 3: Preventing complications of diabetes. *Medical journal of Australia* 2003;179(9):498-505.
10. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-Year Natural History of Type 1 Diabetes Complications The Pittsburgh Epidemiology of Diabetes Complications Study Experience. *Diabetes* 2006;55(5):1463-1469.
11. Stephenson J, Fuller JH, Group EICS. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. *Diabetologia* 1994;37(3):278-285.
12. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemc threshold.

- 1
2
3 *Kidney international* 2001;60(1):219-227.
- 4 13. Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C,
5 Reunanen A. Incidence of cardiovascular disease in Type 1 (insulin-dependent)
6 diabetic subjects with and without diabetic nephropathy in Finland. *Diabetologia*
7 1998;41(7):784-790.
- 8 14. Hovind P, Tarnow L, Rossing P, Graae M, Torp I, Binder C, Parving H-H.
9 Predictors for the development of microalbuminuria and macroalbuminuria in patients
10 with type 1 diabetes: inception cohort study. *Bmj* 2004;328(7448):1105.
- 11 15. Malik MO, Govan L, Petrie JR, Ghouri N, Leese G, Fischbacher C, Colhoun H,
12 Philip S, Wild S, McCrimmon R. Ethnicity and risk of cardiovascular disease (CVD):
13 4.8 year follow-up of patients with type 2 diabetes living in Scotland. *Diabetologia*
14 2015;58(4):716-725.
- 15 16. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic
16 complications. *Current diabetes reports* 2013;13(6):814-823.
- 17 17. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage
18 Renal Disease in the United States, National Institutes of Health, National Institute of
19 Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003.
- 20 18. Young BA, Katon WJ, Von Korff M, Simon GE, Lin EHB, Ciechanowski PS,
21 Bush T, Oliver M, Ludman EJ, Boyko EJ. Racial and ethnic differences in
22 microalbuminuria prevalence in a diabetes population: the pathways study. *Journal of*
23 *the American Society of Nephrology* 2005;16(1):219-228.
- 24 19. Lin W-H, Wang M-C, Wang W-M, Yang D-C, Lam C-F, Roan J-N, Li C-Y.
25 Incidence of and Mortality from Type I Diabetes in Taiwan From 1999 through 2010:
26 A Nationwide Cohort Study. *PloS one* 2014;9(1):e86172.
- 27 20. Cheng T-M. Taiwan's new national health insurance program: genesis and
28 experience so far. *Health Affairs* 2003;22(3):61-76.
- 29 21. Vella S, Buetow L, Royle P, Livingstone S, Colhoun H, Petrie J. The use of
30 metformin in type 1 diabetes: a systematic review of efficacy. *Diabetologia*
31 2010;53(5):809-820.
- 32 22. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with
33 type 1 diabetes. *Diabetes Care* 2005;28(7):1562-1567.
- 34 23. Gail MH, Benichou J. *Encyclopedia of epidemiologic methods*: John Wiley &
35 Sons; 2000.
- 36 24. Sahai H, Khurshid A. *Statistics in epidemiology: methods, techniques and*
37 *applications*: CRC press; 1995.

- 1
2
3 25. Graves EJ, Gillum BS. Detailed diagnoses and procedures, National Hospital
4 Discharge Survey, 1995. *Vital Health Stat 13* 1997(130):1-146.
- 5
6 26. Javor KA, Kotsanos JG, McDonald RC, Baron AD, Kesterson JG, Tierney WM.
7 Diabetic ketoacidosis charges relative to medical charges of adult patients with type I
8 diabetes. *Diabetes Care* 1997;20(3):349-354.
- 9
10 27. Rewers A, Chase HP, Mackenzie T, Walravens P, Roback M, Rewers M,
11 Hamman RF, Klingensmith G. Predictors of acute complications in children with type
12 1 diabetes. *Jama* 2002;287(19):2511-2518.
- 13
14 28. Neu A, Willasch A, Eehalt S, Hub R, Ranke MB. Ketoacidosis at onset of type
15 1 diabetes mellitus in children—frequency and clinical presentation. *Pediatric diabetes*
16 2003;4(2):77-81.
- 17
18 29. Alaghebandan R, Collins KD, Newhook LA, MacDonald D. Childhood type 1
19 diabetes mellitus in Newfoundland and Labrador, Canada. *Diabetes research and*
20 *clinical practice* 2006;74(1):82-89.
- 21
22 30. Meltzer LJ, Johnson SB, Prine JM, Banks RA, Desrosiers PM, Silverstein JH.
23 Disordered eating, body mass, and glycemic control in adolescents with type 1
24 diabetes. *Diabetes care* 2001;24(4):678-682.
- 25
26 31. Rodin GM, Daneman D. Eating disorders and IDDM: a problematic association.
27 *Diabetes Care* 1992;15(10):1402-1412.
- 28
29 32. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic
30 hypoglycaemia in 411 type 1 diabetic patients. *Diabetic Medicine* 1991;8(3):217-222.
- 31
32 33. Craig ME, Jones TW, Silink M, Ping YJ, International Diabetes Federation
33 Western Pacific Region Steering C. Diabetes care, glycemic control, and
34 complications in children with type 1 diabetes from Asia and the Western Pacific
35 Region. *Journal of Diabetes and its Complications* 2007;21(5):280-287.
- 36
37 34. Aye T, Reiss AL, Kesler S, Hoang S, Drobny J, Park Y, Schleifer K, Baumgartner
38 H, Wilson DM, Buckingham BA. The feasibility of detecting neuropsychologic and
39 neuroanatomic effects of type 1 diabetes in young children. *Diabetes care*
40 2011;34(7):1458-1462.
- 41
42 35. Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA.
43 Neuropsychological profiles of children with type 1 diabetes 6 years after disease
44 onset. *Diabetes care* 2001;24(9):1541-1546.
- 45
46 36. Ho MS, Weller NJ, Ives FJ, Carne CL, Murray K, vanden Driesen RI, Nguyen
47 TP, Robins PD, Bulsara M, Davis EA. Prevalence of structural central nervous system
48 abnormalities in early-onset type 1 diabetes mellitus. *The Journal of pediatrics*

- 2008;153(3):385-390.
37. Umpierrez GE, Murphy MB, Kitabchi AE. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. *Diabetes Spectrum* 2002;15(1):28-36.
38. VanNewkirk MR, Weih L, McCarty CA, Taylor HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project. *Ophthalmology* 2001;108(5):960-967.
39. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, 3rd, Klein R, American Diabetes A. Diabetic retinopathy. *Diabetes Care* 2003;26 Suppl 1:S99-S102.
40. Lin J-C, Shau W-Y, Lai M-S. Sex-and age-specific prevalence and incidence rates of sight-threatening diabetic retinopathy in Taiwan. *JAMA ophthalmology* 2014;132(8):922-928.
41. Monti MC, Lonsdale JT, Montomoli C, Montross R, Schlag E, Greenberg DA. Familial risk factors for microvascular complications and differential male-female risk in a large cohort of American families with type 1 diabetes. *The Journal of Clinical Endocrinology & Metabolism* 2007;92(12):4650-4655.
42. Minuto N, Emmanuele V, Vannati M, Russo C, Rebora C, Panarello S, Pistorio A, Lorini R, d'Annunzio G. Retinopathy screening in patients with type 1 diabetes diagnosed in young age using a non-mydriatic digital stereoscopic retinal imaging. *Journal of endocrinological investigation* 2012;35(4):389-394.
43. Holl R, Lang G, Grabert M, Heinze E, Lang G, Debatin K. Diabetic retinopathy in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and pubertal onset of diabetes, and metabolic control. *The Journal of pediatrics* 1998;132(5):790-794.
44. Hletala K, Harjutsalo V, Forsblom C, Groop P-H, Group fs. Age at onset and the risk of proliferative retinopathy in type 1 diabetes. *Diabetes care* 2010;33(6):1315-1319.
45. Marshall SM. Clinical features and management of diabetic nephropathy. *Textbook of diabetes Boston: Blackwell Publishing* 2003;2003.
46. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes—the Linköping Diabetes Complications Study. *Diabetologia* 2004;47(7):1266-1272.
47. Donaghue KC, Fairchild JM, Craig ME, Chan AK, Hing S, Cutler LR, Howard NJ, Silink M. Do all prepubertal years of diabetes duration contribute equally to

- 1
2
3 diabetes complications? *Diabetes care* 2003;26(4):1224-1229.
- 4
5 48. Svensson M, Nyström L, Schön S, Dahlquist G. Age at Onset of
6
7 Childhood-Onset Type 1 Diabetes and the Development of End-Stage Renal Disease
8
9 A nationwide population-based study. *Diabetes Care* 2006;29(3):538-542.
- 10
11 49. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, Holl RW.
12
13 Diabetic Nephropathy in 27,805 Children, Adolescents, and Adults With Type 1
14
15 Diabetes Effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset,
16
17 and sex. *Diabetes care* 2007;30(10):2523-2528.
- 18
19 50. International Comparisons. *American Journal of Kidney*
20
21 *Diseases*;57(1):e383-e396.
- 22
23 51. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT,
24
25 Klein RL, dcct/edic Research G. Lipoproteins in the DCCT/EDIC cohort: associations
26
27 with diabetic nephropathy. *Kidney international* 2003;64(3):817-828.
- 28
29 52. Rossing P, Hougaard P, Parving H-H. Risk Factors for Development of Incipient
30
31 and Overt Diabetic Nephropathy in Type 1 Diabetic Patients A 10-year prospective
32
33 observational study. *Diabetes care* 2002;25(5):859-864.
- 34
35 53. American Diabetes A. Standards of medical care for patients with diabetes
36
37 mellitus. *Puerto Rico Health Sciences Journal* 2013;20(2).
- 38
39 54. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA,
40
41 Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies a statement by the
42
43 American Diabetes Association. *Diabetes care* 2005;28(4):956-962.
- 44
45 55. Veglio M, Sivieri R. Prevalence of neuropathy in IDDM patients in Piemonte,
46
47 Italy. *Diabetes care* 1993;16(2):456-461.
- 48
49 56. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W,
50
51 Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients
52
53 with insulin-treated diabetes. *Diabetologia* 2003;46(6):760-765.
- 54
55 57. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The Effect of
56
57 Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes The Diabetes
58
59 Control and Complications Trial/Epidemiology of Diabetes Interventions and
60
61 Complications Study. *Diabetes care* 2007;30(8):2107-2112.
- 62
63 58. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002.
64
65 *Diabetes care* 2003;26(3):917.
- 66
67 59. Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK,
68
69 Becker DJ, Cavender DE, Drash AL. The Pittsburgh insulin-dependent diabetes
70
71 mellitus (IDDM) morbidity and mortality study: mortality results. *Diabetes*

1
2
3 1984;33(3):271-276.
4

5 60. Borch-Johnsen K, Nissen H, Henriksen E, Kreiner S, Salling N, Deckert T,
6

7
8 Nerup J. The Natural History of Insulin-Dependent Diabetes Mellitus in Denmark: 1.
9

10
11 Long-term survival with and without late diabetic complications. *Diabetic Medicine*
12

13
14 1987;4(3):201-210.

15 61. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing
16 natural history of nephropathy in type I diabetes. *The American journal of medicine*
17 1985;78(5):785-794.
18

19
20 62. Maser RE, Wolfson S, Ellis D, Stein EA, Drash AL, Becker DJ, Dorman JS,
21 Orchard TJ. Cardiovascular disease and arterial calcification in insulin-dependent
22 diabetes mellitus: interrelations and risk factor profiles. Pittsburgh Epidemiology of
23 Diabetes Complications Study-V. *Arteriosclerosis, Thrombosis, and Vascular Biology*
24 1991;11(4):958-965.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Overall incident number and incidence density of diabetes-related complications in patients with type 1 diabetes, 1999-2013

	Retinopathy	Proliferative retinopathy	STDR	Neuropathy	Nephropathy	Renal failure	CVD	DKA	Mild hypoglycemia	Hospitalized hypoglycemia
No. of cases*	3,359	3,970	3,983	3,742	3,634	4,003	3,916	2,205	3,934	3,987
No. of cases with event	1,532	157	90	558	688	36	117	996	913	105
Follow-up time (person-years)†	15,675	26,733	27,139	23,320	21,936	27,491	26,664	8,224	22,865	26,968
Incidence density (1,000 person-years) (95% CI)	97.74 (92.9-102.8)	5.87 (5.0-6.9)	3.32 (2.7-4.1)	23.93 (22.0-26.0)	31.36 (29.1-33.8)	1.31 (0.9-1.8)	4.39 (3.6-5.3)	121.11 (113.7-128.9)	39.93 (37.4-42.6)	3.89 (3.2-4.7)

* No. of cases refers to the number of patients who had no complication of interest in the baseline year (one year before diagnosis year).

† Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.

Note: Patients with type 1 diabetes were retrieved from incidence cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrollment from Taiwan's National Health Insurance Program, or the end of 2013, whichever came first.

Abbreviations: STDR: sight-threatening diabetic retinopathy, CVD: cardiovascular disease, DKA: diabetic ketoacidosis, CI: confidence interval.

Table 2: Age-sex-specific incident number and incidence density of diabetes-related complications in patients with type 1 diabetes, 1999-2013

	Retinopathy	Proliferative retinopathy	STDR	Neuropathy	Nephropathy	Renal failure	CVD	DKA	Mild hypoglycemia	Hospitalized hypoglycemia
Male										
No. of cases*										
All male	1,618	1,886	1,892	1,778	1,695	1,901	1859	1,073	1,872	1,902
Early-onset (0-12 years)	654	719	719	714	700	719	712	396	718	719
Late-onset (≥ 13 years)	964	1,167	1,173	1,064	995	1,182	1,147	677	1,154	1,183
No. of cases with event										
All male	693	64	34	261	332	15	60	447	452	28
Early onset	305	14	1	37	86	1	7	239	202	11
Late onset	388	50	33	224	246	14	53	208	250	17
Follow-up time (person-years)†										
All male	7,813	12,908	13,102	11,345	10,403	13,248	12,798	4,322	11,025	13,115
Early-onset	3,333	5,290	5,368	5,180	4,817	5,358	5,280	1,317	4,277	5,297
Late-onset	4,480	7,618	7,734	6,165	5,586	7,891	7,518	3,005	6,749	7,818
Incidence density (1,000 person-years) (95% CI)										
All male	88.70 (82.2-95.6)	4.96 (3.8-6.3)	2.60 (1.8-3.6)	23.01 (20.3-26.0)	31.91 (28.6-35.5)	1.13 (0.6-1.9)	4.69 (3.6-6.0)	103.43 (94.1-113.5)	41.00 (37.3-45.0)	2.13 (1.4-3.1)
Early-onset	91.52 (81.5-102.4)	2.65 (1.4-4.4)	0.19 (0.0-1.0)	7.14 (5.0-9.8)	17.85 (14.3-22.0)	0.19 (0.0-1.0)	1.33 (0.5-2.7)	181.53 (159.2-206.1)	47.23 (40.9-54.2)	2.08 (1.0-3.7)
Late-onset	86.60 (78.2-95.7)	6.56 (4.9-8.7)	4.27 (2.9-6.0)	36.34 (31.7-41.4)	44.04 (38.7-49.9)	1.77 (1.0-3.0)	7.05 (5.3-9.2)	69.22 (60.1-79.3)	37.05 (32.6-41.9)	2.17 (1.3-3.5)

95% CI of incidence density

difference for male, early vs.

-8.5 to 18.3

-6.4 to -1.4‡

-5.9 to -2.3‡

-34.8 to -23.6‡

-33.1 to -19.3‡

-2.8 to -0.4‡

-8.1 to -3.3‡

91.5 to 133.1‡

2.4 to 17.9‡

-1.7 to 1.5

late-onset

Female

No. of cases*

All female

1,741

2,084

2,091

1,964

1,939

2,102

2,057

1,132

2,062

2,085

Early-onset

721

777

777

772

764

777

773

413

774

774

Late-onset

1,020

1,307

1,314

1,192

1,175

1,325

1,284

719

1,288

1,311

No. of cases with event

All female

839

93

56

297

356

21

57

549

461

77

Early-onset

358

18

6

50

109

1

11

277

229

21

Late-onset

481

75

50

247

247

20

46

272

232

56

Follow-up time (person-years)†

All female

7,862

13,825

14,037

11,976

11,533

14,243

13,866

3,902

11,840

13,853

Early-onset

3,616

5,848

5,910

5,610

5,283

5,927

5,871

1,183

4,642

5,777

Late-onset

4,246

7,977

8,127

6,365

6,250

8,317

7,995

2,719

7,199

8,076

Incidence density

(1,000 person-years)

(95% CI)

All female

106.72

6.73

3.99

24.80

30.87

1.47

4.11

140.69

38.94

5.56

(99.6-114.2)

(5.4-8.2)

(3.0-5.2)

(22.1-27.8)

(27.7-34.2)

(0.9-2.3)

(3.1-5.3)

(129.2-153.0)

(35.5-42.7)

(4.4-6.9)

Early-onset

99.01

3.08

1.02

8.91

20.63

0.17

1.87

234.05

49.34

3.63

(89.0-109.8)

(1.8-4.9)

(0.4-2.2)

(6.6-11.8)

(16.9-24.9)

(0.0-0.9)

(0.9-3.4)

(207.3-263.3)

(43.1-56.2)

(2.3-5.6)

Late-onset

113.29

9.40

6.15

38.80

39.52

2.40

5.75

100.05

32.23

6.93

(103.4-123.9)

(7.4-11.8)

(4.6-8.1)

(34.1-44.0)

(34.7-44.8)

(1.5-3.7)

(4.2-7.7)

(88.5-112.7)

(28.2-36.7)

(5.2-9.0)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47


95% CI of incidence density										
difference for female, early vs. late-onset	-28.8 to 0.2	-9.1 to -3.6‡	-7.3 to -3.0‡	-35.5 to -24.2‡	-25.3 to -12.5‡	-3.5 to -1.0‡	-6.0 to -1.7‡	108.4 to 159.6‡	9.8 to 24.4‡	-5.8 to -0.8‡
95% CI of incidence density										
difference for male vs. female	-27.8 to -8.2‡	-3.6 to 0.1	-2.8 to -0.02‡	-5.8 to 2.2	-3.6 to 5.7	-1.2 to 0.5	-1.0 to 2.2	-52.3 to -22.2‡	-3.1 to 7.2	-4.9 to -1.9‡

* No. of cases refers to the number of patients who had no complication of interest in the baseline year (one year before diagnosis year).

† Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.

Note: Patients with type 1 diabetes were retrieved from incidence cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrollment from Taiwan’s National Health Insurance Program, or the end of 2013, whichever came first.

Abbreviations: STDR: sight-threatening diabetic retinopathy, CVD: cardiovascular disease, DKA: diabetic ketoacidosis, CI: confidence interval. ‡ $p < 0.05$



1
2
3
4 Patients who had a diagnosis of type 1 diabetes (250.x1, 250.x3) from outpatient file of National Health Insurance Research Database (NHIRD) in
5 1999-2013, and had received a Catastrophic Illness Card (CIC) for type 1 diabetes (n = 4,677)
6
7

8
9
10 Exclusion of possible type 2 diabetes (n = 670)

11 ✓ Patients who had at least one prescription of oral hypoglycemic
12 agents (not including metformin and thiazolidinediones) in
13 outpatient file of NHIRD after CIC was issued.
14
15

16
17 Study cohort (n = 4,007)
18

19
20 Exclusion of patients with diagnosis of diabetes-related complications 1
21 year prior to type 1 diabetes diagnosis
22
23
24
25

26
27
28 Type 1 diabetes patients for estimating incidence densities and cumulative incidence rates of diabetes-related complications
29
30
31

32 **Figure 1. Flowchart of study cohort selection**
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47




Figure 2: Cumulative incidences of diabetic ketoacidosis, mild hypoglycemia according to the duration of diabetes in patients with type 1 diabetes

Note: Shadow area indicates 95 % confidence interval.




Figure 3: Cumulative incidences of retinopathy, sight-threatening diabetic retinopathy, neuropathy, nephropathy, renal failure, and cardiovascular diseases according to the duration of diabetes in patients with type 1 diabetes.

Note: Shadow area indicates 95 % confidence interval.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47**Supplementary Table 1: Diabetes-related acute and chronic complications**


Complications	ICD-9-CM disease codes	ICD-9-CM procedure codes	NHI procedure codes
CVD (cardiovascular disease and cerebrovascular disease)^{a,b}			
Acute myocardial infarction	410, 412*	---	---
Ischemic heart disease	411, 413, 414, V45.81, V45.82	00.66, 36.0, 36.1, 36.2, 36.3, 36.9, 88.9	---
Heart failure	428	---	---
Stroke	430-437, 438*, V12.54	00.61, 00.63, 38.11, 38.12	---
Cardiogenic shock	785.51	---	---
Sudden cardiac arrest	V12.53	---	---
Arteriosclerotic cardiovascular disease	429.2	---	---
Arrhythmia	426, 427	---	---
Microvascular complications^{a,c}			
Nephropathy	250.4, 403, 404, 580, 581, 582, 583, 584, 585, 586, 587, 588, 593, 791.0, V13.03, V42.0, V45.1, V56	38.95, 39.27, 39.42, 39.95, 54.98, 55.4, 55.5, 55.6	---
Renal failure (dialysis or transplantation) ^d	V45.1, V56	39.95, 54.98	---
Retinopathy	250.5, 361, 362, 364, 365, 366, 368, 369, 377, 379.2	12.41, 12.73, 14.23, 14.24, 14.25, 14.33, 14.34, 14.35, 14.53, 14.54, 14.55, 16.92, 16.99	86206B, 86207B, 60001C, 60002C*, 60003C, 60004C*
Proliferative retinopathy ^d	362.02	---	60001C, 60002C*, 60003C, 60004C*
Sight-threatening diabetic retinopathy ^e	---	---	86206B, 86207B, 60001C, 60002C*, 60003C, 60004C*
Neuropathy	250.6, 302.72, 337.1, 354, 355, 357.2, 358.1, 607.84, 713.5, 729.2	---	---
Metabolic complications			
Diabetic ketoacidosis ^a	250.1	---	---
Hypoglycemia ^{a,f}	251.0, 251.1, 251.2, 270.3, 775.0, 775.6	---	---


1
2 *For identifying prevalent cases only. a: Nutr Metab Cardiovasc Dis. 2014;24(1):10-7. b: Pharmacoepidemiol Drug Saf. 2009;18(6):497-503. c: Diabetes Care. 2008;31(3):596-615. d: Diabetes. 2006;55(5):1463-9.
3 e: JAMA Ophthalmol. 2014;132(8):922-928. f: BMC Endocr Disord. 2008;8:4. Abbreviations: ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification, NHI: Taiwan National
4 Health Insurance.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



For peer review only


Supplementary Figure 1: Age-sex-specific cumulative incidences of diabetes complications according to duration of diabetes in patients with type 1 diabetes (early-onset: 0-12 years, late-onset: ≥ 13 years)











STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1, 2 2, 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7, 8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	7, 8 Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8, 9
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses	9 9, 10 9, 10 9 9, 10

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Continued on next page

For peer review only

Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10, 11
		(b) Report category boundaries when continuous variables were categorized	10, 11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	21
Generalisability	21	Discuss the generalisability (external validity) of the study results	21
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Incidence of diabetes-related complications in ethnic Chinese with newly diagnosed type 1 diabetes: A claim-based cohort of diabetes from 1999 to 2013

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015117.R1
Article Type:	Research
Date Submitted by the Author:	10-Mar-2017
Complete List of Authors:	Ou, Huang-tz; National Cheng Kung University College of Medicine, Institute of Clinical Pharmacy and Pharmaceutical Sciences ; National Cheng Kung University College of Medicine, Pharmacy Lee, Tsung-Ying ; National Cheng Kung University College of Medicine, Institute of Clinical Pharmacy and Pharmaceutical Sciences Li, Chung-Yi; National Cheng Kung University College of Medicine, Public Health; China Medical University, Public Health Wu, Jin Shang ; National Cheng Kung University College of Medicine, Family Medicine; National Cheng Kung University Hospital, Family Medicine Sun, Zih Jie ; National Cheng Kung University Hospital, Family Medicine; National Cheng Kung University Hospital Dou-Liou Branch, Family Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Health services research
Keywords:	DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Diabetic neuropathy < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Incidence of diabetes-related complications in ethnic Chinese with newly diagnosed type**
4 **1 diabetes: A claim-based cohort of diabetes from 1999 to 2013**
5

6
7
8 Huang-Tz Ou PhD^{1,2,*}, Tsung-Ying Lee MS¹, Chung-Yi Li PhD^{3,4}, Jin-Shang Wu MD^{5,6},
9 Zih-Jie Sun MD^{6,7}
10

11
12 ¹Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National
13 Cheng Kung University, Tainan, Taiwan

14
15 ²Department of Pharmacy, College of Medicine, National Cheng Kung University Tainan,
16 Taiwan

17
18 ³Department of Public Health, College of Medicine, National Cheng Kung University, Tainan,
19 Taiwan

20
21 ⁴Department of Public Health, China Medical University, Taichung, Taiwan

22
23 ⁵Department of Family Medicine, College of Medicine, National Cheng Kung University,
24 Tainan, Taiwan

25
26 ⁶Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan

27
28 ⁷Department of Family Medicine, National Cheng Kung University Hospital, Dou-Liou
29 Branch, Dou-Liou, Taiwan
30

31
32
33
34
35
36 ****Corresponding author***

37 Huang-Tz Ou, PhD

38
39 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National
40 Cheng Kung University,

41
42 1 University Road, Tainan 7010, Taiwan

43
44 Phone: +886-6-2353535 ext.5685

45
46 Fax: +886-6-2373149

47
48 Email: huangtz@mail.ncku.edu.tw
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To estimate the incidence densities and cumulative incidence of diabetes-related complications in patients with type 1 diabetes for a maximum of 15-year follow-up. The estimations were further stratified by gender and age at diagnosis (i.e., early-onset: 0-12 years, late-onset: ≥ 13 years).

Design: A population-based longitudinal cohort study.

Setting: Taiwan's National Health Insurance medical claims.

Participants: 4,007 patients newly-diagnosed with type 1 diabetes were identified during 1999-2012.

Outcome measures: Acute complications included diabetic ketoacidosis (DKA) and hypoglycemia. Chronic complications were cardiovascular diseases (CVD), retinopathy, neuropathy, and nephropathy.

Results: The incidence density of retinopathy was greatest (97.74 per 1,000 person-years), followed by those of nephropathy (31.36), neuropathy (23.93), and CVD (4.39). Among acute complications, the incidence density of DKA was greatest (121.11 per 1,000 person-years). The cumulative incidences of acute complications after 12 years following diagnosis were estimated to be 52.1%, 36.1%, and 4.1% for DKA, outpatient hypoglycemia,

1
2
3
4 and hospitalized hypoglycemia, respectively. For chronic complications, the cumulative
5
6
7 incidence of retinopathy after 12 years following diagnosis was greatest (65.2%), followed by
8
9
10 those of nephropathy (30.2%), neuropathy (23.7%), and CVD (4.1%). Females with
11
12
13 late-onset diabetes were greatly affected by advanced retinopathy (i.e., sight-threatening
14
15
16 diabetic retinopathy) and hospitalized hypoglycemia, whereas those with early-onset diabetes
17
18
19 were more vulnerable to DKA. Chronic complications were more commonly seen in
20
21
22 late-onset diabetes, whereas early-onset diabetes were most affected by acute complications.
23

24
25 **Conclusions:** Ethnically Chinese patients with type 1 diabetes were greatly affected by DKA
26
27
28 and retinopathy. The incidence of diabetes-related complications after diagnosis differed by
29
30
31 age and sex.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- ✓ This is the largest longitudinal cohort study of ethnically Chinese patients with type 1 diabetes followed for a maximum of 15 years to provide up-to-date incidence estimates of acute and chronic complications.
- ✓ The analyses stratified by gender and age at diabetes-onset indicated significant age-gender disparities in the epidemiological data of diabetes-related complications in type 1 diabetes, which highlight importance for clinical attention and developing preventive strategies.
- ✓ The study limitations resulting from the use of medical reimbursement claims data, including potential misclassifications of diabetes-related complications and lack of clinical biomarkers such as blood glucose, may underestimate rather than overestimate the incidence rates of diabetes-related complications.
- ✓ The incidence estimates of diabetes-related complications may only be generalizable to ethnically Chinese population with type 1 diabetes.

Introduction

It has been estimated that the incidence of type 1 diabetes increases by about 3-5% per year worldwide.¹⁻³ The annual incidence rate of childhood (< 15 years) type 1 diabetes in Taiwan was 5.3 per 100,000 children in the period 2003-2008.⁴ Type 1 diabetes accounts for only 5-10% of the diabetic population, but it remains a devastating chronic disorder with acute complications, including diabetic ketoacidosis (DKA) and hypoglycemia, and chronic complications, which can be divided into microvascular (i.e., retinopathy, neuropathy, nephropathy) and macrovascular complications (i.e., cardiovascular diseases; CVD). Although treatment and care for type 1 diabetes have improved,⁵⁻⁷ diabetes-related complications are major obstacles to glycemic control for many patients and contribute to most of the increased morbidity and premature mortality in such individuals.⁸ The toxicity effect of prolonged chronic hyperglycemia is a leading cause of microvascular and macrovascular diseases among type 1 diabetes patients, with hypertension and dyslipidemia being exacerbating factors.⁹

Assessing the epidemiology of diabetes-related complications is essential for developing preventive strategies and planning treatment protocols to minimize the impact of the complications. However, there is very little longitudinal data (e.g., Pittsburgh Epidemiology

1
2
3
4 of Childhood-Onset Diabetes Complications (EDC) Study,¹⁰ EURODIAB IDDM
5
6
7 Complications Study¹¹) on the incidence of complications for type 1 diabetes, and previous
8
9
10 estimates widely varied with countries (e.g., European countries,¹² Finland,¹³ Denmark,¹⁴
11
12
13 United States¹⁰) and entailed different follow-up periods (e.g., 7 years,¹² 12 years,¹³ 18
14
15
16 years,¹⁴ and 30 years¹⁰). In addition, a limited number of diabetes-related complications have
17
18
19 been investigated (e.g., microalbuminuria^{12, 14} and cardiovascular diseases; CVD¹³), with no
20
21
22 previous study targeting an ethnic Chinese population with type 1 diabetes. Ethnic variations
23
24
25 in diabetes-related complications have been recognized; Caucasian patients are greatly
26
27
28 affected by CVD,^{15, 16} while the prevalence of end-stage renal failure (ESRD)¹⁷ and the odds
29
30
31 of microalbuminuria and macroalbuminuria¹⁸ in Asian populations are much higher compared
32
33
34 to those for Caucasian patients. Given the significance of rising life expectancy in recent
35
36
37 years among ethnic Chinese patients with type 1 diabetes,¹⁹ it is important to provide precise
38
39
40 up-to-date estimates of incidence of its complications and compare them to those for other
41
42
43 countries. We therefore utilized a longitudinal population-based cohort of newly diagnosed
44
45
46 type 1 diabetes patients who were followed during the period 1999-2013 to evaluate the
47
48
49 incidence densities and cumulative incidences of acute and chronic complications to provide
50
51
52 contemporary estimates for an ethnic Chinese population. Efforts were also made to examine
53
54
55
56
57
58
59
60

1
2
3
4 whether there were age and sex differences in the incidences of type-1-diabetes-related
5
6
7 complications.
8
9
10
11
12

13 **Materials and Methods**

14
15
16 The Institutional Review Board of National Cheng Kung University Hospital approved
17
18
19 the study before commencement (A-ER-103-298).
20
21

22 Data source:

23
24
25 We utilized the Longitudinal Cohort of Diabetes Patients (LHDB) 1996-2013 data from
26
27
28 the National Health Insurance Research Database (NHIRD). Taiwan's NHIRD is
29
30
31 population-based and derived from the claims data of the National Health Insurance (NHI)
32
33
34 program, a mandatory-enrollment, single-payment system that covers over 99% of Taiwan's
35
36
37 population.²⁰ The LHDB is a valid national dataset that consists of a random sample of
38
39
40 120,000 de-identified diabetes incident cases from each calendar year, who were tracked back
41
42
43 to 1996 and followed up to 2013 to establish a longitudinal cohort. The LHDB is
44
45
46 representative of Taiwan's population with diabetes and provides research opportunity to
47
48
49 evaluate long-term health outcomes of patients.²¹⁻²⁶
50
51
52

53 Cohort:

1
2
3
4 From the LHDB, we selected 4,677 patients with a diagnosis of type 1 diabetes
5
6
7 (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM =
8
9
10 250.x1 or 250.x3) from outpatient files of the LHDB and having received a Catastrophic
11
12
13 Illness Card (CIC) for type 1 diabetes (Figure 1) in the period 1999-2012. Because patients
14
15
16 with a CIC are eligible for exemption from co-payments, the approval of such a status is
17
18
19 subject to evaluation and review by the Bureau of NHI of Taiwan. The CIC patient data are
20
21
22 accurate and reliable with a positive predictive value of 98.3% for type 1 diabetes.¹⁹ We
23
24
25 further excluded 670 potential type 2 diabetes cases who consumed any oral
26
27
28 antihypoglycemic agents (OHAs) after CIC was issued, including sulfonylureas, meglitinides,
29
30
31 acarbose, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide-1 receptor agonists,
32
33
34 and however, those who used metformin alone, thiazolidinediones alone, or both were
35
36
37 retained. Patients who were prescribed metformin, thiazolidinediones, or both were retained
38
39
40 because these OHAs are insulin-sensitizers that can be combined with insulin treatments for
41
42
43 cases with insulin resistance,^{27,28} which is also seen in patients with type 1 diabetes in Taiwan
44
45
46 based on our expert opinions. To estimate the incidence rates of diabetes-related
47
48
49 complications, we further selected cases without a history of microvascular or macrovascular
50
51
52 diseases before type 1 diabetes diagnosis (Table 1). Study patients were stratified by gender
53
54
55
56
57
58
59
60

1
2
3
4 and age at first type 1 diabetes diagnosis (i.e., early-onset: 0-12 years, late-onset: ≥ 13 years).

5
6
7 The 25th, 50th (median) and 75th percentiles of age in early-onset group were 5, 8, and 10,

8
9
10 respectively, with the mean age of 7.69 (standard deviation: 3.22). And, for late-onset group,

11
12
13 the 25th, 50th and 75th percentiles of age were 17, 24, and 33, respectively, with the mean age

14
15
16 of 26.47 (standard deviation: 11.60).

17 18 19 Diabetes-related complications:

20
21
22 The complications of interest included acute complications, namely DKA (confirmed by
23
24 hospital admission or emergency room visit for DKA), hypoglycemia (confirmed by defined
25
26 hypoglycemic events required for outpatient visits or hospitalization for medical assistance or
27
28 interventions), and chronic complications, namely CVD, nephropathy, retinopathy, and
29
30 neuropathy. A list of diabetes-related complications and the corresponding ICD-9-CM codes
31
32 are provided in Supplementary Table 1; this list was confirmed by the expert panel before
33
34 being applied.
35
36
37
38
39
40
41
42
43

44 45 Statistics:

46
47 The incidence density of diabetes-related complications was calculated by dividing the
48
49 number of incident cases with individual complication events by the total person-years
50
51 observed over 15 years of follow-up (1999-2013). The 95% confidence intervals (CIs) were
52
53
54
55
56
57
58
59
60

1
2
3
4 calculated assuming a Poisson distribution of cases.²⁹ Significant differences in incidence
5
6
7 density between age-sex subgroups were indicated by a 95% CI for the difference in
8
9
10 incidence density between subgroups.³⁰ Moreover, because a cohort of newly diagnosed type
11
12
13 1 diabetes patients was utilized, we were able to provide visual illustrations about the
14
15
16 cumulative incidences of diabetes-related complications by diabetes duration since diabetes
17
18
19 onset. The cumulative incidence of diabetes-related complications was estimated by using the
20
21
22 life table method (using the SAS LIFETEST procedure) and significant difference in
23
24
25 cumulative incidence between subgroups were examined according to K-sample tests.³¹ SAS
26
27
28 version 9.4 (SAS Institute Inc., Cary, NC) was used for the aforementioned analyses.
29
30
31
32
33
34

35 **Results**

36
37
38 The overall and age-sex specific incidence densities of diabetes-related complications
39
40
41 are presented in Tables 1 and 2, respectively. The incidence rate of retinopathy (97.74 per
42
43
44 1,000 person-years) was greatest, followed by those of nephropathy (31.36), neuropathy
45
46
47 (23.93), and CVD (4.39). Among acute complications, the incidence density of DKA was
48
49
50 greatest (121.11 per 1,000 person-years). As shown in Table 2, the incidence densities of
51
52
53 retinopathy, DKA, and hospitalized hypoglycemia in females were significantly higher than
54
55
56
57
58
59
60

1
2
3
4 those in males. The incidence densities of DKA and outpatient hypoglycemia in the
5
6
7 early-onset group (0-12 years) were significantly higher than those noted in the late-onset
8
9
10 group (≥ 13 years), while those of advanced retinopathy (i.e., sight-threatening diabetic
11
12
13 retinopathy; STDR), neuropathy, nephropathy, CVD, and hospitalized hypoglycemia in the
14
15
16 late-onset group were significantly higher. Figures 2 and 3 show cumulative incidences for
17
18
19 acute and chronic complications, respectively, along with diabetes duration. The cumulative
20
21
22 incidences at the 12th year after diagnosis were 52.1%, 36.1%, and 4.1% for DKA, outpatient
23
24
25 hypoglycemia, and hospitalized hypoglycemia, respectively. For chronic complications, the
26
27
28 12-year cumulative incidence of retinopathy was greatest (65.2%), followed by those of
29
30
31 nephropathy (30.2%), neuropathy (23.7%), and CVD (5.2%). Age-sex specific cumulative
32
33
34 incidences of diabetes-related complications are illustrated in Supplementary Figure 1.
35
36
37
38
39
40

41 Discussion

42
43
44 To the best of our knowledge, this is the largest cohort study of ethnically Chinese
45
46
47 patients with newly diagnosed type 1 diabetes. We provided up-to-date estimates of the
48
49
50 incidence of acute and chronic complications in type 1 diabetes patients followed for a
51
52
53 maximum of 15 years. We observed age-gender disparities in the incidence of
54
55
56
57
58
59
60

1
2
3
4 diabetes-related complications in type 1 diabetes. Although comparisons of the epidemiology
5
6
7 of diabetes-related complications between studies are difficult, as potential determinants of
8
9
10 the complications (e.g., age, gender, diabetes duration) differ, the estimates from different
11
12
13 studies may reveal some racial or ethnic differences. In the following, we compare our results
14
15
16 for ethnically Chinese patients with those reported for other countries or ethnicities.
17

18 19 **Acute diabetes-related complications in type 1 diabetes patients**

20 21 22 *Diabetic ketoacidosis*

23
24
25 Among acute complications, hyperglycemic events, including DKA and hyperglycemic
26
27
28 hyperosmolar syndrome (HHS), are leading causes of morbidity and mortality among
29
30
31 individuals with diabetes,³² and utilize significant healthcare resources.³³ DKA was the most
32
33
34 common acute complication among the Taiwanese population with type 1 diabetes; the
35
36
37 incidence density followed for 15 years was 121.11 per 1,000 person-years, and half of the
38
39
40 study population (~52%) experienced DKA at 12 years after diabetes diagnosis. Consistent
41
42
43 with previous studies from the United States,³⁴ Australia,³⁵ and Canada,³⁶ we found that the
44
45
46 incidence of DKA in female patients, especially those with early-onset diabetes (i.e., 0-12
47
48
49 years), was higher than that in male patients. A cohort of 1,234 children with type 1 diabetes
50
51
52 in the United States showed that female patients were greatly affected by DKA. A female
53
54
55
56
57
58
59
60

1
2
3
4 preponderance of DKA was observed in a longitudinal study of childhood type 1 diabetes in
5
6
7 Australia.³⁵ Similarly, a Canadian study of childhood type 1 diabetes showed that female sex
8
9
10 was a significant predictor of DKA.³⁶ In fact, insulin omission or intentional insulin
11
12
13 under-treatment due to fear of weight gain³⁷ and high prevalence of eating disorders³⁸ and
14
15
16 psychiatric disorders³⁴ among female type 1 diabetes patients have been recognized as
17
18
19 precipitating causes of DKA. Hence, effective interventions such as health education and
20
21
22 communication for type 1 diabetes females are needed to reduce the incidence of DKA.
23

24 25 26 *Hypoglycemia*

27
28
29 Increased hypoglycemic events have been recognized as a result of the undesired effects
30
31
32 of intensive insulin therapy with strict glycaemic control.³⁹ The present study showed that the
33
34
35 incidence rates of hospitalized and outpatient hypoglycemia in the Taiwanese population with
36
37
38 type 1 diabetes were 3.89 and 39.93 per 1,000 person-years, respectively, which are much
39
40
41 lower than that reported in type 1 diabetes children (0-19 years) in the United States
42
43
44 (incidence of severe hypoglycemia: 190 per 1,000 person-years).³⁴ Such discrepancies in
45
46
47 international data may be explained by different definitions and assessment approaches for
48
49
50 hypoglycemic events. We targeted hospital admissions for hypoglycemia based on ICD-9 CM
51
52
53 codes, whereas the United States study used patients' reported survey data and classified
54
55
56
57
58
59
60

1
2
3
4 severe hypoglycemia as acute episodes requiring the assistance of another person for
5
6
7 treatment reported in the preceding 3 months.⁴⁰
8
9

10
11 Moreover, we observed that early-onset patients were greatly affected by acute
12
13 complications (i.e., DKA, hypoglycemia). It has been documented that among young children
14
15 with type 1 diabetes, inconsistent eating patterns and lesser ability to recognize and report
16
17 acute symptoms make it difficult to achieve glycemic control, leading to glycemic
18
19 fluctuations that cause multiple episodes of hyperglycemia (i.e., DKA) and hypoglycemia.⁴¹
20
21
22
23
24
25 Frequent exposures to hyperglycemia and hypoglycemia in early-onset type 1 diabetes
26
27
28 patients could lead to a range of neurocognitive dysfunctions and brain changes.⁴² Also,
29
30
31 structural brain changes in type 1 diabetes children may occur due to recurrent
32
33
34 hypoglycemia.⁴³ Hence, given the high rates of acute complications and associated serious
35
36
37 consequences, effective management protocols and identification and treatment of
38
39 precipitating causes are needed.⁴⁴ In particular, regular glycemic monitoring and
40
41
42
43 identification of risk factors in young type 1 diabetes patients are needed to reduce the
44
45
46
47 frequency and severity of DKA and hypoglycemia.
48
49

50 **Chronic diabetes-related complications in type 1 diabetes**

51 *Diabetic retinopathy*

1
2
3
4 Diabetic retinopathy is the main cause of blindness in the adult population.⁴⁵ Almost all
5
6
7 type 1 diabetes patients develop evident retinopathy in the first 20 years of diagnosis.⁴⁶ The
8
9
10 present study showed that more than half (~69%) of type 1 diabetes patients experienced
11
12
13 some form of diabetic retinopathy at 12 years after diagnosis. We observed that the incidence
14
15
16 density of diabetes retinopathy is greatest among chronic complications in Taiwanese type 1
17
18
19 diabetes patients (4.53 per 100 person-years over a period of 15 years of follow-up). As
20
21
22 compared to the incident density of proliferative retinopathy (19.5 per 1,000 person-years) in
23
24
25 the Pittsburgh EDC Study of type 1 diabetes patients with a mean age of 28 years and
26
27
28 diabetes duration of 19 years at baseline examination,¹⁰ our estimate (5.87 per 1,000
29
30
31 person-year) based on a cohort of newly diagnosed type 1 diabetes patients is lower. Such a
32
33
34 difference between studies may be explained by diabetes duration and age at baseline of
35
36
37 study examination. Moreover, comparing the prevalence of STDR in type 1 diabetes patients
38
39
40 in this study (2.00 % for women and 1.66 % for men) with that previously observed in
41
42
43 Taiwanese type 2 diabetes patients (2.75% for women and 2.87% for men)⁴⁷ reveals a slightly
44
45
46 lower advanced diabetic retinopathy (i.e., STDR) in the type 1 diabetes versus type 2 diabetes
47
48
49 patients. However, the lower rate of STDR in our study may be due to the other study's
50
51
52 inclusion of prevalent type 2 diabetes cases with longer diabetes duration⁴⁷ as compared to
53
54
55
56
57
58
59
60

1
2
3
4 incident type 1 diabetes targeted in this study.
5

6
7 Consistent with previous studies,^{48,49} the present study demonstrated a female
8
9
10 preponderance in diabetic retinopathy. A large cohort of 8,114 type 1 diabetes patients and
11
12 families assembled over 25 years from the United States showed that females had 1.7 fold
13
14 higher retinopathy risk ($p < 0.001$) as compared to that of males.⁴⁸ Also, a cross-sectional
15
16 study of 247 Italian type 1 diabetes patients showed a significant relationship between
17
18 diabetic retinopathy and female gender ($p = 0.01$).⁴⁹ Although exact hormone, genetic,
19
20 lifestyle, or environmental factors are unclear, a differential effect of sex steroid hormones
21
22 has been proposed to explain this gender discrepancy.⁵⁰ Also, age at diabetes onset has been
23
24 shown to be associated with the development of diabetic retinopathy.^{49,51} An early age at
25
26 onset (5-14 years) appears to modify the long-term risk of proliferative retinopathy.⁵¹
27
28
29 Consistent with other studies, we observed lower incidence of diabetic retinopathy in
30
31 early-onset patients as compared to that in late-onset patients. Nevertheless, given a high rate
32
33 of diabetes retinopathy observed among Taiwanese type 1 diabetes patients, early detection
34
35 using routine eye examination, control for risk factors of diabetic retinopathy (e.g.,
36
37 hypertension, hyperglycemia, hyperlipidemia),⁹ as well as development of tailored
38
39 intervention strategies for age-sex subgroups are important.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diabetic nephropathy

Our results show that diabetic nephropathy is the second most common microvascular complication among the Taiwanese population with type 1 diabetes. Without interventions, diabetes patients with microalbuminuria typically progress to proteinuria and overt diabetic nephropathy.⁵² Diabetic nephropathy is a leading cause of ESRD among patients with diabetes.⁵² As estimated, individuals with type 1 diabetes face a 20-50% chance of developing ESDR that requires dialysis or renal transplantation.⁵³ The Pittsburgh EDC Study reported that the incidence density of renal failure (based on self-reported renal transplantation and dialysis) was 6.3 per 1,000 person-years over 12 years of follow-up,¹⁰ while the present study based on ICD-9 codes of renal failure found that the incidence of renal failure was 1.31 per 1,000 person-years over 15 years of follow-up. Of note, the EDC study enrolled more advanced type 1 diabetes cases (i.e., mean age of 28 years and diabetes duration of 19 years at baseline examination¹⁰) than those in our study (i.e., newly diagnosed type 1 diabetes cases in 2000-2012), which may explain the higher rate of renal failure in the EDC study. A large inception cohort study of Danish patients newly diagnosed with type 1 diabetes followed for a median of 18 years reported that the cumulative incidences of persistent microalbuminuria and macroalbuminuria were 33.6% and 14.6%, respectively,

1
2
3
4 while the present study found that overall cumulative incidence of any form of diabetic
5
6
7 nephropathy was 30.2% at 12 years after diabetes diagnosis. Moreover, early-onset diabetes
8
9
10 appears to be protective for developing diabetic nephropathy^{12, 54-56} and may delay the time
11
12
13 until microalbuminuria.⁵⁶ Consistently, we found that late-onset diabetes patients were more
14
15
16 affected by diabetic nephropathy than were early-onset patients. Nevertheless, given the fact
17
18
19 that Taiwan has the highest number of patients undergoing renal dialysis in the world, where
20
21
22 diabetes contributes to about 40 % of end-stage renal failure cases,⁵⁷ it is critical for routine
23
24
25 annual screening of clinical signs of diabetic nephropathy (i.e., proteinuria,
26
27
28 microalbuminuria), optimal control of glycemia and risk factors (e.g., retinopathy smoking,
29
30
31 dyslipidemia, hypertension^{14, 58, 59}), and early intervening medications for prevention (e.g.,
32
33
34 angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for those with
35
36
37 comorbid hypertension).⁹

41 *Diabetic neuropathy*

42
43
44 Diabetic neuropathy refers to the presence of symptoms, signs, or both of peripheral
45
46
47 nerve dysfunction in people with diabetes after the exclusion of other causes.⁶⁰ Peripheral
48
49
50 neuropathy in diabetes may manifest in several different forms, including sensory,
51
52
53 focal/multifocal, and autonomic neuropathies.⁶¹ The epidemiological data of diabetic
54
55
56
57
58
59
60

1
2
3
4 neuropathy is very limited. A study of 467 Italian type 1 diabetes patients showed that the
5
6
7 prevalence rates of asymptomatic and symptomatic neuropathy were 7.2% and 21.3%,
8
9
10 respectively.⁶² The present study is the first study to provide epidemiology data on diabetic
11
12
13 neuropathy among ethnically Chinese patients with type 1 diabetes from Asia. We found that
14
15
16 the incidence rate was 23.93 per 1,000 person-years over 15 years of follow-up, and that the
17
18
19 cumulative incidence was 23.7% at 12 years after diabetes diagnosis. We also observed that
20
21
22 the incidence of diabetic neuropathy in late-onset patients were much higher than that in
23
24
25 early-onset patients. Similarly, the Italian study of type 1 diabetes showed that the prevalence
26
27
28 of diabetic neuropathy was higher in patients at older ages.⁶² Since diabetic neuropathy
29
30
31 contributes to considerable disabilities and mortality, it is critical for clinicians to understand
32
33
34 its manifestations, prevention, and treatment.⁹ Early prevention strategies that control
35
36
37 hypertension and hyperglycemia and identify patients with peripheral neuropathy or
38
39
40 peripheral vascular disease and annual screening for these conditions are strongly
41
42
43 recommended.⁹
44
45

46 47 *Cardiovascular diseases*

48
49
50 CVD is a leading cause of mortality in patients with type 1 diabetes^{63, 64} and accounts for
51
52
53 the greatest proportion of healthcare spending for patients with diabetes.^{64, 65} As compared to
54
55
56

1
2
3
4 patients without diabetes, type 1 diabetes increases the risk of CVD by ten fold,^{63, 66} which
5
6
7 contributes to two-thirds of mortality in patients with type 1 diabetes.^{67, 68} The Pittsburgh
8
9
10 EDC Study showed an incidence density of 3.6 per 1,000 person-years for coronary heart
11
12
13 diseases (defined as coronary-artery-disease-related death, a history of myocardial infarction,
14
15
16 angiographic stenosis $\geq 50\%$ including revascularization) over a period of 12 years,¹⁰ while
17
18
19 the present study found that the incidence density for a broader category of CVD (including
20
21
22 myocardial infarction, ischemic heart diseases, heart failure, stroke, and arrhythmia, as shown
23
24
25 in Supplementary Table 1) in the Taiwanese population with type 1 diabetes within 15 years
26
27
28 of follow-up was 4.39 per 1,000 person-years. The cumulative incidences of CVD (including
29
30
31 only stroke and coronary heart disease) at 12 years after diabetes was diagnosed was 1-2%
32
33
34 among Finnish type 1 diabetes patients,¹³ which is lower than that for the Taiwanese type 1
35
36
37 diabetes patients in the present study (~5.2%). Moreover, we found that late-onset patients
38
39
40 were greatly affected by CVD. In fact, old age is recognized as a predictor of vascular
41
42
43 diseases,⁶³ which may be explained by the calcification of extremity arteries and hypertension
44
45
46 in older age patients, which are risk factors of macrovascular diseases.⁶⁹
47
48
49

50 51 **Methodological concerns**

52
53
54 Some limitations of this study should be acknowledged. The classification of
55
56
57

1
2
3
4 diabetes-related complications based on the ICD-9 CM codes in claims data may
5
6
7 underestimate the occurrence of the complications. For example, patients experiencing
8
9
10 clinical symptoms/signs of diabetes-related complications (e.g., hypoglycemia) may not see
11
12
13 doctors if they can tolerate them. Also, the claims data do not capture clinical/minor
14
15
16 symptoms or signs of diabetes-related complications such as minor microalbuminuria. The
17
18
19 glycemic biomarkers such as blood glucose were not available from the claims data so the
20
21
22 identification of hyperglycemia or hypoglycemia was only based on the ICD-9 CM diagnosis
23
24
25 codes. So, we might under-estimate the incidence of hypoglycemic events and may not be
26
27
28 able to disentangle the severity of hypoglycemia. However, the claims records capture
29
30
31 defined diabetes-related complications that are required for medical assistance or treatments,
32
33
34 which lead to more conservative estimates and reveal important manifestations of
35
36
37 diabetes-related complications for clinical attention. Moreover, based on our operational
38
39
40 definition for hospitalized hypoglycemia (i.e., any one of diagnosis codes with hypoglycemia
41
42
43 from the five diagnosis codes in the inpatient files of the NHIRD), two types of
44
45
46 hypoglycemic events could be included: (1) hospital admission for hypoglycemia, and (2)
47
48
49 other reasons for hospital admission (e.g., DKA), and then hypoglycemia happened during
50
51
52 hospitalization. It is difficult to differentiate these two types of hypoglycemic events based on
53
54
55
56
57
58
59
60

1
2
3
4 the retrospective claims data we utilized. However, in the clinical practice in Taiwan, the first
5
6
7 code from the five diagnosis codes in hospitalization is typically to be the main/primary
8
9
10 reason for hospital admission. With this regard, we re-run the analyses for hospitalized
11
12
13 hypoglycemia which was identified from the first diagnosis code in hospitalization. The
14
15
16 results were provided in the Supplementary Table 2, and Supplementary Figures 2 and 3.
17
18
19 These re-analytical results may also ease the concern that patients who came to hospital
20
21
22 primarily for reasons that may induce hypoglycemia during hospitalization. Lastly, the
23
24
25 generalizability of our study results may be limited to ethnically Chinese populations. In
26
27
28 addition, our results may represent only ethnically Chinese patients with type 1 diabetes in
29
30
31 Taiwan.

32 33 34 35 **Conclusions**

36
37
38 Utilizing an incident cohort of type 1 diabetes patients diagnosed during the period
39
40
41 1999-2012 with a maximum of 15 years of follow-up, we found that most type 1 diabetes
42
43
44 patients were affected by DKA and retinopathy, which highlight the critical need to identify
45
46
47 precipitating causes and modifiable factors for developing preventive strategies and
48
49
50 intervening treatment protocols to minimize the impact of these complications. Age and sex
51
52
53 discrepancies appear in epidemiological data of diabetes-related complications; late-onset
54
55
56
57
58
59
60

1
2
3
4 diabetes females were greatly affected by advanced retinopathy (i.e., STDR) and hospitalized
5
6
7 hypoglycemia, while early-onset females had a high incidence of DKA. Chronic
8
9
10 diabetes-related complications were more common in late-onset type 1 diabetes patients,
11
12
13 while early-onset individuals were most affected by acute complications. More attention
14
15
16 should be given to identify potential risk factors and contributors to such age-sex differences
17
18
19 in diabetes-related complications. Population-based data on the incidence of diabetes-related
20
21
22 complications from this study are important for clinicians to recognize the need for diagnostic
23
24
25 awareness and for policy-makers to develop effective treatments for patients with type 1
26
27
28
29 diabetes.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Acknowledgments:** We gratefully thank National Cheng Kung University and its affiliated
5
6
7 hospital for all their support.
8
9

10
11
12
13 **Funding:** This research was supported by the Ministry of Science and Technology, Taiwan,
14
15
16 grant MOST 104-2320-B-006-008-MY3.
17
18

19
20
21
22 **Competing interests:** No declared.
23
24

25
26
27
28 **Authors' contribution:** H.T.O. contributed substantially to the study concept and design,
29
30 acquisition of data, analysis and interpretation of data. T.Y.L. contributed to data collection
31
32 and the analysis. C.Y.L., J.S.W., and Z.J.S. provided statistical and clinical interpretation of
33
34 the results. H.T.O. wrote the first draft of the manuscript, and T.Y.L., C.Y.L., J.S.W., and
35
36 Z.J.S. very critically revised the manuscript. All authors gave approval for the publication of
37
38 the final version.

39
40 **Data sharing statement:** There are no additional data available in relation to this
41
42 manuscript.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of Type I diabetes—the analysis of the data on published incidence trends. *Diabetologia* 1999;42(12):1395-1403.
2. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. *Diabetes care* 2000;23(10):1516-1526.
3. Soltesz G, Patterson CC, Dahlquist G. Worldwide childhood type 1 diabetes incidence—what can we learn from epidemiology? *Pediatric diabetes* 2007;8(s6):6-14.
4. Lu CL, Shen HN, Chen HF, Li CY. Epidemiology of childhood Type 1 diabetes in Taiwan, 2003 to 2008. *Diabetic Medicine* 2014;31(6):666-673.
5. Goldstein DE, Walker B, Rawlings SS, Hess RL, England JD, Peth SB, Hewett JE. Hemoglobin A1c levels in children and adolescents with diabetes mellitus. *Diabetes Care* 1980;3(4):503-507.
6. Ziegler R, Heidtmann B, Hilgard D, Hofer S, Rosenbauer J, Holl R. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. *Pediatric diabetes* 2011;12(1):11-17.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *New England Journal of Medicine* 1993;329(20):1456-1462.
8. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-Cause Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 Diabetes The Allegheny County Type 1 Diabetes Registry. *Diabetes care* 2010;33(12):2573-2579.
9. Bate KL, Jerums G. 3: Preventing complications of diabetes. *Medical journal of Australia* 2003;179(9):498-505.
10. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-Year Natural History of Type 1 Diabetes Complications The Pittsburgh Epidemiology of Diabetes Complications Study Experience. *Diabetes* 2006;55(5):1463-1469.
11. Stephenson J, Fuller JH, Group EICS. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. *Diabetologia* 1994;37(3):278-285.
12. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemetic threshold.

1
2
3 *Kidney international* 2001;60(1):219-227.

- 4 13. Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C,
5 Reunanen A. Incidence of cardiovascular disease in Type 1 (insulin-dependent)
6 diabetic subjects with and without diabetic nephropathy in Finland. *Diabetologia*
7 1998;41(7):784-790.
- 8 14. Hovind P, Tarnow L, Rossing P, Graae M, Torp I, Binder C, Parving H-H.
9 Predictors for the development of microalbuminuria and macroalbuminuria in patients
10 with type 1 diabetes: inception cohort study. *Bmj* 2004;328(7448):1105.
- 11 15. Malik MO, Govan L, Petrie JR, Ghouri N, Leese G, Fischbacher C, Colhoun H,
12 Philip S, Wild S, McCrimmon R. Ethnicity and risk of cardiovascular disease (CVD):
13 4.8 year follow-up of patients with type 2 diabetes living in Scotland. *Diabetologia*
14 2015;58(4):716-725.
- 15 16. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic
16 complications. *Current diabetes reports* 2013;13(6):814-823.
- 17 17. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage
18 Renal Disease in the United States, National Institutes of Health, National Institute of
19 Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003.
- 20 18. Young BA, Katon WJ, Von Korff M, Simon GE, Lin EHB, Ciechanowski PS,
21 Bush T, Oliver M, Ludman EJ, Boyko EJ. Racial and ethnic differences in
22 microalbuminuria prevalence in a diabetes population: the pathways study. *Journal of*
23 *the American Society of Nephrology* 2005;16(1):219-228.
- 24 19. Lin W-H, Wang M-C, Wang W-M, Yang D-C, Lam C-F, Roan J-N, Li C-Y.
25 Incidence of and Mortality from Type I Diabetes in Taiwan From 1999 through 2010:
26 A Nationwide Cohort Study. *PloS one* 2014;9(1):e86172.
- 27 20. Cheng T-M. Taiwan's new national health insurance program: genesis and
28 experience so far. *Health Affairs* 2003;22(3):61-76.
- 29 21. Ou H-T, Chang K-C, Li C-Y, Wu J-S. Risks of cardiovascular diseases associated
30 with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with
31 type 2 diabetes: a nation-wide longitudinal study. *Cardiovascular diabetology*
32 2016;15(1):41.
- 33 22. Ou HT, Chang KC, Liu YM, Wu JS. Recent trends in the use of antidiabetic
34 medications from 2008 to 2013: A nation-wide population-based study from Taiwan.
35 *Journal of diabetes* 2016.
- 36 23. Hou W-H, Chang K-C, Li C-Y, Ou H-T. Dipeptidyl peptidase-4 inhibitor use is
37 not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 population-based cohort study. *Pain* 2016;157(9):1954-1959.
- 4 24. Ou H-T, Yang C-Y, Wang J-D, Hwang J-S, Wu J-S. Life Expectancy and
5 Lifetime Health Care Expenditures for Type 1 Diabetes: A Nationwide Longitudinal
6 Cohort of Incident Cases Followed for 14 Years. *Value in Health* 2016;19(8):976-984.
- 7 25. Ou HT, Chang KC, Li CY, Wu JS. Comparative cardiovascular risks of
8 dipeptidyl peptidase-4 inhibitors with other 2nd and 3rd line antidiabetic drugs in
9 patients with type 2 diabetes. *British Journal of Clinical Pharmacology* 2017.
- 10 26. Ou H-T, Chen Y-T, Liu Y-M, Wu J-S. Comparative cost-effectiveness of
11 metformin-based dual therapies associated with risk of cardiovascular diseases among
12 Chinese patients with type 2 diabetes: Evidence from a population-based national
13 cohort in Taiwan. *Diabetes Research and Clinical Practice* 2016;116:14-25.
- 14 27. Vella S, Buetow L, Royle P, Livingstone S, Colhoun H, Petrie J. The use of
15 metformin in type 1 diabetes: a systematic review of efficacy. *Diabetologia*
16 2010;53(5):809-820.
- 17 28. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with
18 type 1 diabetes. *Diabetes Care* 2005;28(7):1562-1567.
- 19 29. Gail MH, Benichou J. *Encyclopedia of epidemiologic methods*: John Wiley &
20 Sons; 2000.
- 21 30. Sahai H, Khurshid A. *Statistics in epidemiology: methods, techniques and*
22 *applications*: CRC press; 1995.
- 23 31. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a
24 competing risk. *The Annals of statistics* 1988:1141-1154.
- 25 32. Graves EJ, Gillum BS. Detailed diagnoses and procedures, National Hospital
26 Discharge Survey, 1995. *Vital Health Stat 13* 1997(130):1-146.
- 27 33. Javor KA, Kotsanos JG, McDonald RC, Baron AD, Kesterson JG, Tierney WM.
28 Diabetic ketoacidosis charges relative to medical charges of adult patients with type I
29 diabetes. *Diabetes Care* 1997;20(3):349-354.
- 30 34. Rewers A, Chase HP, Mackenzie T, Walravens P, Roback M, Rewers M,
31 Hamman RF, Klingensmith G. Predictors of acute complications in children with type
32 1 diabetes. *Jama* 2002;287(19):2511-2518.
- 33 35. Neu A, Willasch A, Ehehalt S, Hub R, Ranke MB. Ketoacidosis at onset of type
34 1 diabetes mellitus in children—frequency and clinical presentation. *Pediatric diabetes*
35 2003;4(2):77-81.
- 36 36. Alaghebandan R, Collins KD, Newhook LA, MacDonald D. Childhood type 1
37 diabetes mellitus in Newfoundland and Labrador, Canada. *Diabetes research and*

- 1
2
3 *clinical practice* 2006;74(1):82-89.
- 4 37. Meltzer LJ, Johnson SB, Prine JM, Banks RA, Desrosiers PM, Silverstein JH.
5 Disordered eating, body mass, and glycemic control in adolescents with type 1
6 diabetes. *Diabetes care* 2001;24(4):678-682.
- 7
8 38. Rodin GM, Daneman D. Eating disorders and IDDM: a problematic association.
9 *Diabetes Care* 1992;15(10):1402-1412.
- 10
11 39. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic
12 hypoglycaemia in 411 type 1 diabetic patients. *Diabetic Medicine* 1991;8(3):217-222.
- 13
14 40. Craig ME, Jones TW, Silink M, Ping YJ, International Diabetes Federation
15 Western Pacific Region Steering C. Diabetes care, glycemic control, and
16 complications in children with type 1 diabetes from Asia and the Western Pacific
17 Region. *Journal of Diabetes and its Complications* 2007;21(5):280-287.
- 18
19 41. Aye T, Reiss AL, Kesler S, Hoang S, Drobny J, Park Y, Schleifer K, Baumgartner
20 H, Wilson DM, Buckingham BA. The feasibility of detecting neuropsychologic and
21 neuroanatomic effects of type 1 diabetes in young children. *Diabetes care*
22 2011;34(7):1458-1462.
- 23
24 42. Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA.
25 Neuropsychological profiles of children with type 1 diabetes 6 years after disease
26 onset. *Diabetes care* 2001;24(9):1541-1546.
- 27
28 43. Ho MS, Weller NJ, Ives FJ, Carne CL, Murray K, vanden Driesen RI, Nguyen
29 TP, Robins PD, Bulsara M, Davis EA. Prevalence of structural central nervous system
30 abnormalities in early-onset type 1 diabetes mellitus. *The Journal of pediatrics*
31 2008;153(3):385-390.
- 32
33 44. Umpierrez GE, Murphy MB, Kitabchi AE. Diabetic ketoacidosis and
34 hyperglycemic hyperosmolar syndrome. *Diabetes Spectrum* 2002;15(1):28-36.
- 35
36 45. VanNewkirk MR, Weih L, McCarty CA, Taylor HR. Cause-specific prevalence
37 of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project.
38 *Ophthalmology* 2001;108(5):960-967.
- 39
40 46. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD,
41 Ferris FL, 3rd, Klein R, American Diabetes A. Diabetic retinopathy. *Diabetes Care*
42 2003;26 Suppl 1:S99-S102.
- 43
44 47. Lin J-C, Shau W-Y, Lai M-S. Sex-and age-specific prevalence and incidence
45 rates of sight-threatening diabetic retinopathy in Taiwan. *JAMA ophthalmology*
46 2014;132(8):922-928.
- 47
48 48. Monti MC, Lonsdale JT, Montomoli C, Montross R, Schlag E, Greenberg DA.

- 1
2
3 Familial risk factors for microvascular complications and differential male-female
4 risk in a large cohort of American families with type 1 diabetes. *The Journal of*
5 *Clinical Endocrinology & Metabolism* 2007;92(12):4650-4655.
- 6
7
8 49. Minuto N, Emmanuele V, Vannati M, Russo C, Rebora C, Panarello S, Pistorio A,
9 Lorini R, d'Annunzio G. Retinopathy screening in patients with type 1 diabetes
10 diagnosed in young age using a non-mydriatic digital stereoscopic retinal imaging.
11 *Journal of endocrinological investigation* 2012;35(4):389-394.
- 12
13
14 50. Holl R, Lang G, Grabert M, Heinze E, Lang G, Debatin K. Diabetic retinopathy
15 in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and
16 pubertal onset of diabetes, and metabolic control. *The Journal of pediatrics*
17 1998;132(5):790-794.
- 18
19
20 51. Hletala K, Harjutsalo V, Forsblom C, Groop P-H, Group fs. Age at onset and the
21 risk of proliferative retinopathy in type 1 diabetes. *Diabetes care*
22 2010;33(6):1315-1319.
- 23
24
25 52. Marshall SM. Clinical features and management of diabetic nephropathy.
26 *Textbook of diabetes Boston: Blackwell Publishing* 2003;2003.
- 27
28
29 53. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of
30 severe retinopathy and persisting decrease of nephropathy in an unselected population
31 of Type 1 diabetes—the Linköping Diabetes Complications Study. *Diabetologia*
32 2004;47(7):1266-1272.
- 33
34
35 54. Donaghue KC, Fairchild JM, Craig ME, Chan AK, Hing S, Cutler LR, Howard
36 NJ, Silink M. Do all prepubertal years of diabetes duration contribute equally to
37 diabetes complications? *Diabetes care* 2003;26(4):1224-1229.
- 38
39
40 55. Svensson M, Nyström L, Schön S, Dahlquist G. Age at Onset of
41 Childhood-Onset Type 1 Diabetes and the Development of End-Stage Renal Disease
42 A nationwide population-based study. *Diabetes Care* 2006;29(3):538-542.
- 43
44
45 56. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, Holl RW.
46 Diabetic Nephropathy in 27,805 Children, Adolescents, and Adults With Type 1
47 Diabetes Effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset,
48 and sex. *Diabetes care* 2007;30(10):2523-2528.
- 49
50
51 57. International Comparisons. *American Journal of Kidney*
52 *Diseases*;57(1):e383-e396.
- 53
54
55 58. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT,
56 Klein RL, dcct/edic Research G. Lipoproteins in the DCCT/EDIC cohort: associations
57 with diabetic nephropathy. *Kidney international* 2003;64(3):817-828.

- 1
2
3 59. Rossing P, Hougaard P, Parving H-H. Risk Factors for Development of Incipient
4 and Overt Diabetic Nephropathy in Type 1 Diabetic Patients A 10-year prospective
5 observational study. *Diabetes care* 2002;25(5):859-864.
6
7
8 60. American Diabetes A. Standards of medical care for patients with diabetes
9 mellitus. *Puerto Rico Health Sciences Journal* 2013;20(2).
10
11 61. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA,
12 Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies a statement by the
13 American Diabetes Association. *Diabetes care* 2005;28(4):956-962.
14
15 62. Veglio M, Sivieri R. Prevalence of neuropathy in IDDM patients in Piemonte,
16 Italy. *Diabetes care* 1993;16(2):456-461.
17
18 63. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W,
19 Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients
20 with insulin-treated diabetes. *Diabetologia* 2003;46(6):760-765.
21
22 64. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The Effect of
23 Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes The Diabetes
24 Control and Complications Trial/Epidemiology of Diabetes Interventions and
25 Complications Study. *Diabetes care* 2007;30(8):2107-2112.
26
27 65. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002.
28 *Diabetes care* 2003;26(3):917.
29
30 66. Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK,
31 Becker DJ, Cavender DE, Drash AL. The Pittsburgh insulin-dependent diabetes
32 mellitus (IDDM) morbidity and mortality study: mortality results. *Diabetes*
33 1984;33(3):271-276.
34
35 67. Borch-Johnsen K, Nissen H, Henriksen E, Kreiner S, Salling N, Deckert T,
36 Nerup J. The Natural History of Insulin-Dependent Diabetes Mellitus in Denmark: 1.
37 Long-term survival with and without late diabetic complications. *Diabetic Medicine*
38 1987;4(3):201-210.
39
40 68. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing
41 natural history of nephropathy in type I diabetes. *The American journal of medicine*
42 1985;78(5):785-794.
43
44 69. Maser RE, Wolfson S, Ellis D, Stein EA, Drash AL, Becker DJ, Dorman JS,
45 Orchard TJ. Cardiovascular disease and arterial calcification in insulin-dependent
46 diabetes mellitus: interrelations and risk factor profiles. Pittsburgh Epidemiology of
47 Diabetes Complications Study-V. *Arteriosclerosis, Thrombosis, and Vascular Biology*
48 1991;11(4):958-965.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Overall incidence density of diabetes-related complications among patients with type 1 diabetes between 1999 and 2013

	Retinopathy	Proliferative retinopathy	STDR	Neuropathy	Nephropathy	Renal failure	CVD	DKA	Outpatient hypoglycemia	Hospitalized hypoglycemia
No. of cases*	3,359	3,970	3,983	3,742	3,634	4,003	3,916	2,205	3,934	3,987
No. of cases with event**	1,532	157	90	558	688	36	117	996	913	105
Follow-up time (person-years)†	15,675	26,733	27,139	23,320	21,936	27,491	26,664	8,224	22,865	26,968
Incidence density (1,000 person-years) (95% CI)	97.74 (92.9-102.8)	5.87 (5.0-6.9)	3.32 (2.7-4.1)	23.93 (22.0-26.0)	31.36 (29.1-33.8)	1.31 (0.9-1.8)	4.39 (3.6-5.3)	121.11 (113.7-128.9)	39.93 (37.4-42.6)	3.89 (3.2-4.7)

* No. of cases refers to the number of patients who had no complication of interest in the baseline year (one year before diagnosis date).

** No. of cases with event refers to the number of patients who had incident events after type 1 diabetes was confirmed.

† Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.

Note: Patients with type 1 diabetes were retrieved from incidence cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrollment from Taiwan's National Health Insurance Program, or the end of 2013, whichever came first.

Abbreviations: STDR: sight-threatening diabetic retinopathy, CVD: cardiovascular disease, DKA: diabetic ketoacidosis, CI: confidence interval.

Table 2: Incidence density of diabetes-related complications by age and sex among patients with type 1 diabetes between 1999 and 2013

	Retinopathy	Proliferative retinopathy	STDR	Neuropathy	Nephropathy	Renal failure	CVD	DKA	Outpatient hypoglycemia	Hospitalized hypoglycemia
Male										
No. of cases*										
All male	1,618	1,886	1,892	1,778	1,695	1,901	1859	1,073	1,872	1,902
Early-onset (0-12 years)	654	719	719	714	700	719	712	396	718	719
Late-onset (≥ 13 years)	964	1,167	1,173	1,064	995	1,182	1,147	677	1,154	1,183
No. of cases with event**										
All male	693	64	34	261	332	15	60	447	452	28
Early onset	305	14	1	37	86	1	7	239	202	11
Late onset	388	50	33	224	246	14	53	208	250	17
Follow-up time (person-years)†										
All male	7,813	12,908	13,102	11,345	10,403	13,248	12,798	4,322	11,025	13,115
Early-onset	3,333	5,290	5,368	5,180	4,817	5,358	5,280	1,317	4,277	5,297
Late-onset	4,480	7,618	7,734	6,165	5,586	7,891	7,518	3,005	6,749	7,818
Incidence density (1,000 person-years) (95% CI)										
All male	88.70 (82.2-95.6)	4.96 (3.8-6.3)	2.60 (1.8-3.6)	23.01 (20.3-26.0)	31.91 (28.6-35.5)	1.13 (0.6-1.9)	4.69 (3.6-6.0)	103.43 (94.1-113.5)	41.00 (37.3-45.0)	2.13 (1.4-3.1)
Early-onset	91.52	2.65	0.19	7.14	17.85	0.19	1.33	181.53	47.23	2.08
										33

1											
2		(81.5-102.4)	(1.4-4.4)	(0.0-1.0)	(5.0-9.8)	(14.3-22.0)	(0.0-1.0)	(0.5-2.7)	(159.2-206.1)	(40.9-54.2)	(1.0-3.7)
3											
4	Late-onset	86.60	6.56	4.27	36.34	44.04	1.77	7.05	69.22	37.05	2.17
5											
6		(78.2-95.7)	(4.9-8.7)	(2.9-6.0)	(31.7-41.4)	(38.7-49.9)	(1.0-3.0)	(5.3-9.2)	(60.1-79.3)	(32.6-41.9)	(1.3-3.5)
7	95% CI of incidence density										
8	difference for male, early vs.	-8.5 to 18.3	-6.4 to -1.4‡	-5.9 to -2.3‡	-34.8 to -23.6‡	-33.1 to -19.3‡	-2.8 to -0.4‡	-8.1 to -3.3‡	91.5 to 133.1‡	2.4 to 17.9‡	-1.7 to 1.5
9	late-onset										
10											
11											
12	Female										
13											
14	No. of cases*										
15											
16	All female	1,741	2,084	2,091	1,964	1,939	2,102	2,057	1,132	2,062	2,085
17											
18	Early-onset	721	777	777	772	764	777	773	413	774	774
19											
20	Late-onset	1,020	1,307	1,314	1,192	1,175	1,325	1,284	719	1,288	1,311
21	No. of cases with event**										
22											
23	All female	839	93	56	297	356	21	57	549	461	77
24											
25	Early-onset	358	18	6	50	109	1	11	277	229	21
26											
27	Late-onset	481	75	50	247	247	20	46	272	232	56
28	Follow-up time (person-years)†										
29											
30	All female	7,862	13,825	14,037	11,976	11,533	14,243	13,866	3,902	11,840	13,853
31											
32	Early-onset	3,616	5,848	5,910	5,610	5,283	5,927	5,871	1,183	4,642	5,777
33											
34	Late-onset	4,246	7,977	8,127	6,365	6,250	8,317	7,995	2,719	7,199	8,076
35	Incidence density										
36											
37	(1,000 person-years)										
38	(95% CI)										
39											

1											
2	All female	106.72	6.73	3.99	24.80	30.87	1.47	4.11	140.69	38.94	5.56
3											
4		(99.6-114.2)	(5.4-8.2)	(3.0-5.2)	(22.1-27.8)	(27.7-34.2)	(0.9-2.3)	(3.1-5.3)	(129.2-153.0)	(35.5-42.7)	(4.4-6.9)
5	Early-onset	99.01	3.08	1.02	8.91	20.63	0.17	1.87	234.05	49.34	3.63
6											
7		(89.0-109.8)	(1.8-4.9)	(0.4-2.2)	(6.6-11.8)	(16.9-24.9)	(0.0-0.9)	(0.9-3.4)	(207.3-263.3)	(43.1-56.2)	(2.3-5.6)
8	Late-onset	113.29	9.40	6.15	38.80	39.52	2.40	5.75	100.05	32.23	6.93
9											
10		(103.4-123.9)	(7.4-11.8)	(4.6-8.1)	(34.1-44.0)	(34.7-44.8)	(1.5-3.7)	(4.2-7.7)	(88.5-112.7)	(28.2-36.7)	(5.2-9.0)
11											
12	95% CI of incidence density										
13	difference for female, early vs.	-28.8 to 0.2	-9.1 to -3.6‡	-7.3 to -3.0‡	-35.5 to -24.2‡	-25.3 to -12.5‡	-3.5 to -1.0‡	-6.0 to -1.7‡	108.4 to 159.6‡	9.8 to 24.4‡	-5.8 to -0.8‡
14	late-onset										
15	95% CI of incidence density										
16	difference for male vs. female	-27.8 to -8.2‡	-3.6 to 0.1	-2.8 to -0.02‡	-5.8 to 2.2	-3.6 to 5.7	-1.2 to 0.5	-1.0 to 2.2	-52.3 to -22.2‡	-3.1 to 7.2	-4.9 to -1.9‡
17											
18											
19											

* No. of cases refers to the number of patients who had no complication of interest in the baseline year (one year before diagnosis date).

** No. of cases with event refers to the number of patients who had incident events after type 1 diabetes was confirmed.

† Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.

Note: Patients with type 1 diabetes were retrieved from incidence cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrollment from Taiwan's National Health Insurance Program, or the end of 2013, whichever came first.

Abbreviations: STDR: sight-threatening diabetic retinopathy, CVD: cardiovascular disease, DKA: diabetic ketoacidosis, CI: confidence interval. ‡ $p < 0.05$

1 **Figure 1. Flowchart of study cohort selection**

2
3 **Figure 2: Cumulative incidences of diabetic ketoacidosis, mild hypoglycemia according to the**
4 **duration of diabetes in patients with type 1 diabetes (shadow area indicates 95 % confidence interval)**

5
6
7
8 **Figure 3: Cumulative incidences of retinopathy, sight-threatening diabetic retinopathy, neuropathy,**
9 **nephropathy, renal failure, and cardiovascular diseases according to the duration of diabetes in**
10 **patients with type 1 diabetes (shadow area indicates 95 % confidence interval)**

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flowchart of study cohort selection

209x148mm (300 x 300 DPI)

new only




Figure 2: Cumulative incidences of diabetic ketoacidosis, mild hypoglycemia according to the duration of diabetes in patients with type 1 diabetes (shadow area indicates 95 % confidence interval)

209x148mm (300 x 300 DPI)

new only




Figure 3: Cumulative incidences of retinopathy, sight-threatening diabetic retinopathy, neuropathy, nephropathy, renal failure, and cardiovascular diseases according to the duration of diabetes in patients with type 1 diabetes (shadow area indicates 95 % confidence interval)

297x420mm (300 x 300 DPI)

Supplementary Table 1: Diabetes-related acute and chronic complications

Complications	ICD-9-CM disease codes	ICD-9-CM procedure codes	NHI procedure codes
CVD (cardiovascular disease and cerebrovascular disease)^{a,b}			
Acute myocardial infarction	410, 412*	---	---
Ischemic heart disease	411, 413, 414, V45.81, V45.82	00.66, 36.0, 36.1, 36.2, 36.3, 36.9, 88.5	---
Heart failure	428	---	---
Stroke	430-437, 438*, V12.54	00.61, 00.63, 38.11, 38.12	---
Cardiogenic shock	785.51	---	---
Sudden cardiac arrest	V12.53	---	---
Arteriosclerotic cardiovascular disease	429.2	---	---
Arrhythmia	426, 427	---	---
Microvascular complications^{a,c}			
Nephropathy	250.4, 403, 404, 580, 581, 582, 583, 584, 585, 586, 587, 588, 593, 791.0, V13.03, V42.0, V45.1, V56	38.95, 39.27, 39.42, 39.95, 54.98, 55.4, 55.5, 55.6	---
Renal failure (dialysis or transplantation) ^d	V45.1, V56	39.95, 54.98 55.6	---
Retinopathy	250.5, 361, 362, 364, 365, 366, 368, 369, 377, 379.2	12.41, 12.73, 14.23, 14.24, 14.25, 14.33, 14.34, 14.35, 14.53, 14.54, 14.55, 16.92, 16.99	86206B, 86207B, 60001C, 60002C*, 60003C, 60004C*
Proliferative retinopathy ^d	362.02	---	60001C, 60002C*, 60003C, 60004C*
Sight-threatening diabetic retinopathy ^e	---	---	86206B, 86207B, 60001C, 60002C*, 60003C, 60004C*
Neuropathy	250.6, 302.72, 337.1, 354, 355, 357.2, 358.1, 607.84, 713.5, 729.2	---	---
Metabolic complications			
Diabetic ketoacidosis ^a	250.1	---	---
Hypoglycemia ^{a,f}	251.0, 251.1, 251.2, 270.3, 775.0, 775.6	---	---

1 *For identifying prevalent cases only. a: Nutr Metab Cardiovasc Dis. 2014;24(1):10-7. b: Pharmacoepidemiol Drug Saf. 2009;18(6):497-503. c: Diabetes Care. 2008;31(3):596-615. d: Diabetes. 2006;55(5):1463-9.
2 e: JAMA Ophthalmol. 2014;132(8):922-928. f: BMC Endocr Disord. 2008;8:4. Abbreviations: ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification, NHI: Taiwan National
3 Health Insurance.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Supplementary Table 2: Incidence density of hospitalized hypoglycemia among patients with incident type 1 diabetes diagnosed between 1999 and 2013 (using primary diagnosis to define hospitalization for hypoglycemia)

	Overall patients	Male subgroup			Female subgroup		
		Overall male [‡]	Male early-onset (0-12 years) [‡]	Male late-onset (≥13 years)	Overall female	Female early-onset (0-12 years) [‡]	Female late-onset (≥13 years)
No. of cases*	4,001	1,903	719	1,184	2,098	777	1,321
No. of cases with event	36	12	4	8	24	6	18
Follow-up time (person-years)†	27,374	13,205	5,327	7,878	14,169	5,890	8,280
Incidence density (1,000 person-years)	1.32	0.91	0.75	1.02	1.69	1.02	2.17
(95% CI)	(0.9-1.8)	(0.5-1.6)	(0.2-1.9)	(0.4-2.0)	(1.1-2.5)	(0.4-2.2)	(1.3-3.4)

* No. of cases refers to the number of patients who had no complication event of interest before type 1 diabetes was confirmed.


† Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.



Note: Patients with type 1 diabetes were retrieved from incidence cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrollment from Taiwan's National Health Insurance Program, or the end of 2013, whichever came first.

[‡] 95% CI of incidence density difference for male vs. female was [-1.6 to 0.1]; in male subgroup, early vs. late-onset was [-1.3 to 0.8]; and in female subgroup, early vs. late-onset was [-2.5 to 0.2].

Abbreviations: STDR: sight-threatening diabetic retinopathy, CVD: cardiovascular disease, DKA: diabetic ketoacidosis, CI: confidence interval.


Supplementary Figure 1: Age-sex-specific cumulative incidences of diabetes complications according to duration of diabetes in patients with type 1 diabetes (early-onset: 0-12 years, late-onset: ≥ 13 years)








1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



Nephropathy



Renal failure







Note:
 p value for comparison of cumulative incidence of retinopathy for male vs. female was 0.0006, for male, early vs. late-onset was 0.4553, for female, early vs. late-onset was 0.0908.
 p value for comparison of cumulative incidence of proliferative retinopathy for male vs. female was 0.0567, for male, early vs. late-onset was 0.0013, for female, early vs. late-onset was <.0001.

1 *p* value for comparison of cumulative incidence of sight-threatening diabetic retinopathy for male vs. female was 0.0405, for male, early vs. late-onset was
2 <.0001, for female, early vs. late-onset was <.0001.

3 *p* value for comparison of cumulative incidence of neuropathy for male vs. female was 0.4050, for male, early vs. late-onset was <.0001, for female, early vs.
4 late-onset was <.0001.

5 *p* value for comparison of cumulative incidence of nephropathy for male vs. female was 0.6191, for male, early vs. late-onset was <.0001, for female, early vs.
6 late-onset was <.0001.

7 *p* value for comparison of cumulative incidence of renal failure for male vs. female was 0.4222, for male, early vs. late-onset was 0.0078, for female, early vs.
8 late-onset was 0.0003.


9 *p* value for comparison of cumulative incidence of cardiovascular disease for male vs. female was 0.4655, for male, early vs. late-onset was <.0001, for female,
10 early vs. late-onset was 0.0004.

11 *p* value for comparison of cumulative incidence of diabetic ketoacidosis for male vs. female was 0.0015, for male, early vs. late-onset was <.0001, for female,
12 early vs. late-onset was <.0001.

13 *p* value for comparison of cumulative incidence of outpatient hypoglycemia for male vs. female was 0.4095 for male, early vs. late-onset was 0.0097, for
14 female, early vs. late-onset was <.0001.


15 *p* value for comparison of cumulative incidence of hospitalized hypoglycemia for male vs. female was <.0001, for male, early vs. late-onset was 0.9600, for
16 female, early vs. late-onset was 0.0113.

Supplementary Figure 2: Cumulative incidence of hospitalized for hypoglycemia according to the duration of diabetes in patients with type 1 diabetes (shadow area indicates 95 % confidence interval)



Only

Supplementary Figure 3: Age-sex-specific cumulative incidences of hospitalized for hypoglycemia according to duration of diabetes in patients with type 1 diabetes (early-onset: 0-12 years, late-onset: ≥ 13 years)



Note:

p value for comparison of cumulative incidence for male vs. female was 0.0782, for male, early vs. late-onset was 0.6272, for female, early vs. late-onset was 0.1326.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2, 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7, 8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7, 8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8, 9
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9, 10
		(c) Explain how missing data were addressed	9, 10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	9
		(e) Describe any sensitivity analyses	9, 10

Continued on next page

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10, 11
		(b) Report category boundaries when continuous variables were categorized	10, 11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11

Discussion

Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	21
Generalisability	21	Discuss the generalisability (external validity) of the study results	21

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23
---------	----	---------------------------------------------------------------------------------------------------------------------------------------------------------------	----

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Incidence of diabetes-related complications in Chinese patients with type 1 diabetes: A population-based longitudinal cohort study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015117.R2
Article Type:	Research
Date Submitted by the Author:	13-Apr-2017
Complete List of Authors:	Ou, Huang-tz; National Cheng Kung University College of Medicine, Institute of Clinical Pharmacy and Pharmaceutical Sciences ; National Cheng Kung University College of Medicine, Pharmacy Lee, Tsung-Ying ; National Cheng Kung University College of Medicine, Institute of Clinical Pharmacy and Pharmaceutical Sciences Li, Chung-Yi; National Cheng Kung University College of Medicine, Public Health; China Medical University, Public Health Wu, Jin Shang ; National Cheng Kung University College of Medicine, Family Medicine; National Cheng Kung University Hospital, Family Medicine Sun, Zih Jie ; National Cheng Kung University Hospital, Family Medicine; National Cheng Kung University Hospital Dou-Liou Branch, Family Medicine
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology, Health services research
Keywords:	DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Diabetic neuropathy < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Incidence of diabetes-related complications in Chinese patients with type 1 diabetes: A**
4 **population-based longitudinal cohort study in Taiwan**
5
6

7
8 Huang-Tz Ou PhD^{1,2,*}, Tsung-Ying Lee MS¹, Chung-Yi Li PhD^{3,4}, Jin-Shang Wu MD^{5,6},
9 Zih-Jie Sun MD^{6,7}
10

11
12 ¹Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National
13 Cheng Kung University, Tainan, Taiwan

14
15 ²Department of Pharmacy, College of Medicine, National Cheng Kung University Tainan,
16 Taiwan

17
18 ³Department of Public Health, College of Medicine, National Cheng Kung University, Tainan,
19 Taiwan

20
21 ⁴Department of Public Health, China Medical University, Taichung, Taiwan

22
23 ⁵Department of Family Medicine, College of Medicine, National Cheng Kung University,
24 Tainan, Taiwan

25
26 ⁶Department of Family Medicine, National Cheng Kung University Hospital, Tainan, Taiwan

27
28 ⁷Department of Family Medicine, National Cheng Kung University Hospital, Dou-Liou
29 Branch, Dou-Liou, Taiwan
30

31
32
33
34
35
36 ****Corresponding author***

37 Huang-Tz Ou, PhD

38
39 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National
40 Cheng Kung University,

41
42 1 University Road, Tainan 7010, Taiwan

43
44 Phone: +886-6-2353535 ext.5685

45
46 Fax: +886-6-2373149

47
48 Email: huangtz@mail.ncku.edu.tw
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To estimate the incidence densities and cumulative incidence of diabetes-related complications in patients with type 1 diabetes for a maximum of 15-year follow-up. The estimations were further stratified by gender and age at diagnosis (i.e., early-onset: 0-12 years, late-onset: ≥ 13 years).

Design: A population-based retrospective longitudinal cohort study.

Setting: Taiwan's National Health Insurance medical claims.

Participants: 4,007 patients newly-diagnosed with type 1 diabetes were identified during 1999-2012.

Outcome measures: Acute complications included diabetic ketoacidosis (DKA) and hypoglycemia. Chronic complications were cardiovascular diseases (CVD), retinopathy, neuropathy, and nephropathy.

Results: The incidence density of retinopathy was greatest (97.74 per 1,000 person-years), followed by those of nephropathy (31.36), neuropathy (23.93), and CVD (4.39). Among acute complications, the incidence density of DKA was greatest (121.11 per 1,000 person-years). The cumulative incidences of acute complications after 12 years following diagnosis were estimated to be 52.1%, 36.1%, and 4.1% for DKA, outpatient hypoglycemia,

1
2
3
4 and hospitalized hypoglycemia, respectively. For chronic complications, the cumulative
5
6
7 incidence of retinopathy after 12 years following diagnosis was greatest (65.2%), followed by
8
9
10 those of nephropathy (30.2%), neuropathy (23.7%), and CVD (4.1%). Females with
11
12
13 late-onset diabetes were greatly affected by advanced retinopathy (i.e., sight-threatening
14
15
16 diabetic retinopathy) and hospitalized hypoglycemia, whereas those with early-onset diabetes
17
18
19 were more vulnerable to DKA. Chronic complications were more commonly seen in
20
21
22 late-onset diabetes, whereas early-onset diabetes were most affected by acute complications.
23

24
25 **Conclusions:** Ethnically Chinese patients with type 1 diabetes were greatly affected by DKA
26
27
28 and retinopathy. The incidence of diabetes-related complications after diagnosis differed by
29
30
31 age and sex.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- ✓ This is the largest longitudinal cohort study of ethnically Chinese patients with type 1 diabetes followed for a maximum of 15 years to provide up-to-date incidence estimates of acute and chronic complications.
- ✓ The analyses stratified by gender and age at diabetes-onset indicated significant age-gender disparities in the epidemiological data of diabetes-related complications in type 1 diabetes, which highlight importance for clinical attention and developing preventive strategies.
- ✓ The study limitations resulting from the use of medical reimbursement claims data, including potential misclassifications of diabetes-related complications and lack of clinical biomarkers such as blood glucose, may underestimate rather than overestimate the incidence rates of diabetes-related complications.
- ✓ The incidence estimates of diabetes-related complications may only be generalizable to ethnically Chinese population with type 1 diabetes.

1 Introduction

2 It has been estimated that the incidence of type 1 diabetes increases by about 3-5% per
3 year worldwide.¹⁻³ The annual incidence rate of childhood (< 15 years) type 1 diabetes in
4 Taiwan was 5.3 per 100,000 children in the period 2003-2008.⁴ Type 1 diabetes accounts for
5 only 5-10% of the diabetic population, but it remains a devastating chronic disorder with
6 acute complications, including diabetic ketoacidosis (DKA) and hypoglycemia, and chronic
7 complications, which can be divided into microvascular (i.e., retinopathy, neuropathy,
8 nephropathy) and macrovascular complications (i.e., cardiovascular diseases; CVD).
9 Although treatment and care for type 1 diabetes have improved,⁵⁻⁷ diabetes-related
10 complications are major obstacles to glycemic control for many patients and contribute to
11 most of the increased morbidity and premature mortality in such individuals.⁸ The toxicity
12 effect of prolonged chronic hyperglycemia is a leading cause of microvascular and
13 macrovascular diseases among type 1 diabetes patients, with hypertension and dyslipidemia
14 being exacerbating factors.⁹

15 Assessing the epidemiology of diabetes-related complications is essential for developing
16 preventive strategies and planning treatment protocols to minimize the impact of the
17 complications. However, there is very little longitudinal data (e.g., Pittsburgh Epidemiology

1 of Childhood-Onset Diabetes Complications (EDC) Study,¹⁰ EURODIAB IDDM
2 Complications Study¹¹) on the incidence of complications for type 1 diabetes, and previous
3 estimates widely varied with countries (e.g., European countries,¹² Finland,¹³ Denmark,¹⁴
4 United States¹⁰) and entailed different follow-up periods (e.g., 7 years,¹² 12 years,¹³ 18
5 years,¹⁴ and 30 years¹⁰). In addition, a limited number of diabetes-related complications have
6 been investigated (e.g., microalbuminuria^{12, 14} and cardiovascular diseases; CVD¹³), with no
7 previous study targeting an ethnic Chinese population with type 1 diabetes. Ethnic variations
8 in diabetes-related complications have been recognized; Caucasian patients are greatly
9 affected by CVD,^{15, 16} while the prevalence of end-stage renal failure (ESRD)¹⁷ and the odds
10 of microalbuminuria and macroalbuminuria¹⁸ in Asian populations are much higher compared
11 to those for Caucasian patients. Given the significance of rising life expectancy in recent
12 years among ethnic Chinese patients with type 1 diabetes,¹⁹ it is important to provide precise
13 up-to-date estimates of incidence of its complications and compare them to those for other
14 countries. We therefore utilized a longitudinal population-based cohort of newly diagnosed
15 type 1 diabetes patients who were followed during the period 1999-2013 to evaluate the
16 incidence densities and cumulative incidences of acute and chronic complications to provide
17 contemporary estimates for an ethnic Chinese population. Efforts were also made to examine

1
2
3
4 1 whether there were age and sex differences in the incidences of type-1-diabetes-related
5
6
7 2 complications.
8
9

10 3

13 4 **Materials and Methods**

16 5 The Institutional Review Board of National Cheng Kung University Hospital approved
17
18
19 6 the study before commencement (A-ER-103-298).
20
21

22 7 Data source:

25 8 We utilized the Longitudinal Cohort of Diabetes Patients (LHDB) 1996-2013 data from
26
27
28 9 the National Health Insurance Research Database (NHIRD). Taiwan's NHIRD is
29
30
31 10 population-based and derived from the claims data of the National Health Insurance (NHI)
32
33
34 11 program, a mandatory-enrollment, single-payment system that covers over 99% of Taiwan's
35
36
37 12 population.²⁰ The LHDB is a valid national dataset that consists of a random sample of
38
39
40 13 120,000 de-identified diabetes incident cases from each calendar year, who were tracked back
41
42
43 14 to 1996 and followed up to 2013 to establish a longitudinal cohort. The LHDB is
44
45
46 15 representative of Taiwan's population with diabetes and provides research opportunity to
47
48
49 16 evaluate long-term health outcomes of patients.²¹⁻²⁶
50
51
52

53 17 Cohort:

1 From the LHDB, we selected 4,677 patients with a diagnosis of type 1 diabetes
2 (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM =
3 250.x1 or 250.x3) from outpatient files of the LHDB and having received a Catastrophic
4 Illness Card (CIC) for type 1 diabetes (Figure 1) in the period 1999-2012. Because patients
5 with a CIC are eligible for exemption from co-payments, the approval of such a status is
6 subject to evaluation and review by the Bureau of NHI of Taiwan. The CIC patient data are
7 accurate and reliable with a positive predictive value of 98.3% for type 1 diabetes.¹⁹ We
8 further excluded 670 potential type 2 diabetes cases who consumed any oral
9 antihypoglycemic agents (OHAs) after CIC was issued, including sulfonylureas, meglitinides,
10 acarbose, dipeptidyl peptidase 4 inhibitors, and glucagon-like peptide-1 receptor agonists,
11 and however, those who used metformin alone, thiazolidinediones alone, or both were
12 retained. Patients who were prescribed metformin, thiazolidinediones, or both were retained
13 because these OHAs are insulin-sensitizers that can be combined with insulin treatments for
14 cases with insulin resistance,^{27,28} which is also seen in patients with type 1 diabetes in Taiwan
15 based on our expert opinions. To estimate the incidence rates of diabetes-related
16 complications, we further selected cases without a history of the complication before type 1
17 diabetes diagnosis (Table 1). Study patients were stratified by gender and age at first type 1

1 diabetes diagnosis (i.e., early-onset: 0-12 years, late-onset: ≥ 13 years). The 25th, 50th (median)
2 and 75th percentiles of age in early-onset group were 5, 8, and 10, respectively, with the mean
3 age of 7.69 (standard deviation: 3.22). And, for late-onset group, the 25th, 50th and 75th
4 percentiles of age were 17, 24, and 33, respectively, with the mean age of 26.47 (standard
5 deviation: 11.60).

6 Diabetes-related complications:

7 The complications of interest included acute complications, namely DKA (confirmed by
8 hospital admission or emergency room visit for DKA), hypoglycemia (confirmed by defined
9 hypoglycemic events required for outpatient visits or hospitalization for medical assistance or
10 interventions), and chronic complications, namely CVD, nephropathy, retinopathy, and
11 neuropathy. A list of diabetes-related complications and the corresponding ICD-9-CM codes
12 are provided in Supplementary Table 1; this list was confirmed by the expert panel before
13 being applied.

14 Statistics:

15 The incidence density of diabetes-related complications was calculated by dividing the
16 number of incident cases with individual complication events by the total person-years
17 observed over 15 years of follow-up (1999-2013). The 95% confidence intervals (CIs) were

1 calculated assuming a Poisson distribution of cases.²⁹ Significant differences in incidence
2 density between age-sex subgroups were indicated by a 95% CI for the difference in
3 incidence density between subgroups.³⁰ Moreover, because a cohort of newly diagnosed type
4 1 diabetes patients was utilized, we were able to provide visual illustrations about the
5 cumulative incidences of diabetes-related complications by diabetes duration since diabetes
6 onset. The cumulative incidence of diabetes-related complications was estimated by using the
7 life table method (using the SAS LIFETEST procedure) and significant difference in
8 cumulative incidence between subgroups were examined according to K-sample tests.³¹ SAS
9 version 9.4 (SAS Institute Inc., Cary, NC) was used for the aforementioned analyses.

11 **Results**

12 The median (25th and 75th percentiles) for the overall follow-up times (defined as the
13 time from diabetes diagnosis to death, loss-to-follow-up, or the end of study period,
14 whichever came first) are 6.74 years (3.43 and 10.02 years). The overall and age-sex specific
15 incidence densities of diabetes-related complications are presented in Tables 1 and 2,
16 respectively. The incidence rate of retinopathy (97.74 per 1,000 person-years) was greatest,
17 followed by those of nephropathy (31.36), neuropathy (23.93), and CVD (4.39). Among

1 acute complications, the incidence density of DKA was greatest (121.11 per 1,000
2 person-years). As shown in Table 2, the incidence densities of retinopathy, DKA, and
3 hospitalized hypoglycemia in females were significantly higher than those in males. The
4 incidence densities of DKA and outpatient hypoglycemia in the early-onset group (0-12 years)
5 were significantly higher than those noted in the late-onset group (≥ 13 years), while those of
6 advanced retinopathy (i.e., sight-threatening diabetic retinopathy; STDR), neuropathy,
7 nephropathy, CVD, and hospitalized hypoglycemia in the late-onset group were significantly
8 higher. Figures 2 and 3 show cumulative incidences for acute and chronic complications,
9 respectively, along with diabetes duration. The cumulative incidences at the 12th year after
10 diagnosis were 52.1%, 36.1%, and 4.1% for DKA, outpatient hypoglycemia, and hospitalized
11 hypoglycemia, respectively. For chronic complications, the 12-year cumulative incidence of
12 retinopathy was greatest (65.2%), followed by those of nephropathy (30.2%), neuropathy
13 (23.7%), and CVD (5.2%). Age-sex specific cumulative incidences of diabetes-related
14 complications are illustrated in Supplementary Figure 1.

16 Discussion

17 To the best of our knowledge, this is the largest cohort study of ethnically Chinese

1 patients with newly diagnosed type 1 diabetes. We provided up-to-date estimates of the
2 incidence of acute and chronic complications in type 1 diabetes patients followed for a
3 maximum of 15 years. We observed age-gender disparities in the incidence of
4 diabetes-related complications in type 1 diabetes. Although comparisons of the epidemiology
5 of diabetes-related complications between studies are difficult, as potential determinants of
6 the complications (e.g., age, gender, diabetes duration) differ, the estimates from different
7 studies may reveal some racial or ethnic differences. In the following, we compare our results
8 for ethnically Chinese patients with those reported for other countries or ethnicities.

9 **Acute diabetes-related complications in type 1 diabetes patients**

10 *Diabetic ketoacidosis*

11 Among acute complications, hyperglycemic events, including DKA and hyperglycemic
12 hyperosmolar syndrome (HHS), are leading causes of morbidity and mortality among
13 individuals with diabetes,³² and utilize significant healthcare resources.³³ DKA was the most
14 common acute complication among the Taiwanese population with type 1 diabetes; the
15 incidence density followed for 15 years was 121.11 per 1,000 person-years, and half of the
16 study population (~52%) experienced DKA at 12 years after diabetes diagnosis. Consistent
17 with previous studies from the United States,³⁴ Australia,³⁵ and Canada,³⁶ we found that the

1 incidence of DKA in female patients, especially those with early-onset diabetes (i.e., 0-12
2 years), was higher than that in male patients. A cohort of 1,234 children with type 1 diabetes
3 in the United States showed that female patients were greatly affected by DKA. A female
4 preponderance of DKA was observed in a longitudinal study of childhood type 1 diabetes in
5 Australia.³⁵ Similarly, a Canadian study of childhood type 1 diabetes showed that female sex
6 was a significant predictor of DKA.³⁶ In fact, insulin omission or intentional insulin
7 under-treatment due to fear of weight gain³⁷ and high prevalence of eating disorders³⁸ and
8 psychiatric disorders³⁴ among female type 1 diabetes patients have been recognized as
9 precipitating causes of DKA. Hence, effective interventions such as health education and
10 communication for type 1 diabetes females are needed to reduce the incidence of DKA.

11 *Hypoglycemia*

12 Increased hypoglycemic events have been recognized as a result of the undesired effects
13 of intensive insulin therapy with strict glycemic control.³⁹ The present study showed that the
14 incidence rates of hospitalized and outpatient hypoglycemia in the Taiwanese population with
15 type 1 diabetes were 3.89 and 39.93 per 1,000 person-years, respectively, which are much
16 lower than that reported in type 1 diabetes children (0-19 years) in the United States
17 (incidence of severe hypoglycemia: 190 per 1,000 person-years).³⁴ Such discrepancies in

1 international data may be explained by different definitions and assessment approaches for
2 hypoglycemic events. We targeted hospital admissions for hypoglycemia based on ICD-9 CM
3 codes, whereas the United States study used patients' reported survey data and classified
4 severe hypoglycemia as acute episodes requiring the assistance of another person for
5 treatment reported in the preceding 3 months.⁴⁰

6 Moreover, we observed that early-onset patients were greatly affected by acute
7 complications (i.e., DKA, hypoglycemia). It has been documented that among young children
8 with type 1 diabetes, inconsistent eating patterns and lesser ability to recognize and report
9 acute symptoms make it difficult to achieve glycemic control, leading to glycemic
10 fluctuations that cause multiple episodes of hyperglycemia (i.e., DKA) and hypoglycemia.⁴¹
11 Frequent exposures to hyperglycemia and hypoglycemia in early-onset type 1 diabetes
12 patients could lead to a range of neurocognitive dysfunctions and brain changes.⁴² Also,
13 structural brain changes in type 1 diabetes children may occur due to recurrent
14 hypoglycemia.⁴³ Hence, given the high rates of acute complications and associated serious
15 consequences, effective management protocols and identification and treatment of
16 precipitating causes are needed.⁴⁴ In particular, regular glycemic monitoring and
17 identification of risk factors in young type 1 diabetes patients are needed to reduce the

1 frequency and severity of DKA and hypoglycemia.

2 **Chronic diabetes-related complications in type 1 diabetes**

3 *Diabetic retinopathy*

4 Diabetic retinopathy is the main cause of blindness in the adult population.⁴⁵ Almost all
5 type 1 diabetes patients develop evident retinopathy in the first 20 years of diagnosis.⁴⁶ The
6 present study showed that more than half (~69%) of type 1 diabetes patients experienced
7 some form of diabetic retinopathy at 12 years after diagnosis. We observed that the incidence
8 density of diabetes retinopathy is greatest among chronic complications in Taiwanese type 1
9 diabetes patients (4.53 per 100 person-years over a period of 15 years of follow-up). As
10 compared to the incident density of proliferative retinopathy (19.5 per 1,000 person-years) in
11 the Pittsburgh EDC Study of type 1 diabetes patients with a mean age of 28 years and
12 diabetes duration of 19 years at baseline examination,¹⁰ our estimate (5.87 per 1,000
13 person-year) based on a cohort of newly diagnosed type 1 diabetes patients is lower. Such a
14 difference between studies may be explained by diabetes duration and age at baseline of
15 study examination. Moreover, comparing the prevalence of STDR in type 1 diabetes patients
16 in this study (2.00 % for women and 1.66 % for men) with that previously observed in
17 Taiwanese type 2 diabetes patients (2.75% for women and 2.87% for men)⁴⁷ reveals a slightly

1
2
3
4 1 lower advanced diabetic retinopathy (i.e., STDR) in the type 1 diabetes versus type 2 diabetes
5
6
7 2 patients. However, the lower rate of STDR in our study may be due to the other study's
8
9
10 3 inclusion of prevalent type 2 diabetes cases with longer diabetes duration⁴⁷ as compared to
11
12
13 4 incident type 1 diabetes targeted in this study.

14
15
16 5 Consistent with previous studies,^{48, 49} the present study demonstrated a female
17
18
19 6 preponderance in diabetic retinopathy. A large cohort of 8,114 type 1 diabetes patients and
20
21
22 7 families assembled over 25 years from the United States showed that females had 1.7 fold
23
24
25 8 higher retinopathy risk ($p < 0.001$) as compared to that of males.⁴⁸ Also, a cross-sectional
26
27
28 9 study of 247 Italian type 1 diabetes patients showed a significant relationship between
29
30
31 10 diabetic retinopathy and female gender ($p = 0.01$).⁴⁹ Although exact hormone, genetic,
32
33
34 11 lifestyle, or environmental factors are unclear, a differential effect of sex steroid hormones
35
36
37 12 has been proposed to explain this gender discrepancy.⁵⁰ Also, age at diabetes onset has been
38
39
40 13 shown to be associated with the development of diabetic retinopathy.^{49, 51} An early age at
41
42
43 14 onset (5-14 years) appears to modify the long-term risk of proliferative retinopathy.⁵¹
44
45
46 15 Consistent with other studies, we observed lower incidence of diabetic retinopathy in
47
48
49 16 early-onset patients as compared to that in late-onset patients. Nevertheless, given a high rate
50
51
52 17 of diabetes retinopathy observed among Taiwanese type 1 diabetes patients, early detection
53
54
55
56
57
58
59
60

1
2
3
4 1 using routine eye examination, control for risk factors of diabetic retinopathy (e.g.,
5
6
7 2 hypertension, hyperglycemia, hyperlipidemia),⁹ as well as development of tailored
8
9
10 3 intervention strategies for age-sex subgroups are important.
11
12

13 4 *Diabetic nephropathy*

14
15

16 5 Our results show that diabetic nephropathy is the second most common microvascular
17
18
19 6 complication among the Taiwanese population with type 1 diabetes. Without interventions,
20
21
22 7 diabetes patients with microalbuminuria typically progress to proteinuria and overt diabetic
23
24
25 8 nephropathy.⁵² Diabetic nephropathy is a leading cause of ESRD among patients with
26
27
28 9 diabetes.⁵² As estimated, individuals with type 1 diabetes face a 20-50% chance of
29
30
31 10 developing ESDR that requires dialysis or renal transplantation.⁵³ The Pittsburgh EDC Study
32
33
34 11 reported that the incidence density of renal failure (based on self-reported renal
35
36
37 12 transplantation and dialysis) was 6.3 per 1,000 person-years over 12 years of follow-up,¹⁰
38
39
40 13 while the present study based on ICD-9 codes of renal failure found that the incidence of
41
42
43 14 renal failure was 1.31 per 1,000 person-years over 15 years of follow-up. Of note, the EDC
44
45
46 15 study enrolled more advanced type 1 diabetes cases (i.e., mean age of 28 years and diabetes
47
48
49 16 duration of 19 years at baseline examination¹⁰) than those in our study (i.e., newly diagnosed
50
51
52 17 type 1 diabetes cases in 2000-2012), which may explain the higher rate of renal failure in the
53
54
55
56
57
58
59
60

1 EDC study. A large inception cohort study of Danish patients newly diagnosed with type 1
2 diabetes followed for a median of 18 years reported that the cumulative incidences of
3 persistent microalbuminuria and macroalbuminuria were 33.6% and 14.6%, respectively,
4 while the present study found that overall cumulative incidence of any form of diabetic
5 nephropathy was 30.2% at 12 years after diabetes diagnosis. Moreover, early-onset diabetes
6 appears to be protective for developing diabetic nephropathy^{12, 54-56} and may delay the time
7 until microalbuminuria.⁵⁶ Consistently, we found that late-onset diabetes patients were more
8 affected by diabetic nephropathy than were early-onset patients. Nevertheless, given the fact
9 that Taiwan has the highest number of patients undergoing renal dialysis in the world, where
10 diabetes contributes to about 40 % of end-stage renal failure cases,⁵⁷ it is critical for routine
11 annual screening of clinical signs of diabetic nephropathy (i.e., proteinuria,
12 microalbuminuria), optimal control of glycemia and risk factors (e.g., retinopathy smoking,
13 dyslipidemia, hypertension^{14, 58, 59}), and early intervening medications for prevention (e.g.,
14 angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for those with
15 comorbid hypertension).⁹

16 *Diabetic neuropathy*

17 Diabetic neuropathy refers to the presence of symptoms, signs, or both of peripheral

1 nerve dysfunction in people with diabetes after the exclusion of other causes.⁶⁰ Peripheral
2 neuropathy in diabetes may manifest in several different forms, including sensory,
3 focal/multifocal, and autonomic neuropathies.⁶¹ The epidemiological data of diabetic
4 neuropathy is very limited. A study of 467 Italian type 1 diabetes patients showed that the
5 prevalence rates of asymptomatic and symptomatic neuropathy were 7.2% and 21.3%,
6 respectively.⁶² The present study is the first study to provide epidemiology data on diabetic
7 neuropathy among ethnically Chinese patients with type 1 diabetes from Asia. We found that
8 the incidence rate was 23.93 per 1,000 person-years over 15 years of follow-up, and that the
9 cumulative incidence was 23.7% at 12 years after diabetes diagnosis. We also observed that
10 the incidence of diabetic neuropathy in late-onset patients were much higher than that in
11 early-onset patients. Similarly, the Italian study of type 1 diabetes showed that the prevalence
12 of diabetic neuropathy was higher in patients at older ages.⁶² Since diabetic neuropathy
13 contributes to considerable disabilities and mortality, it is critical for clinicians to understand
14 its manifestations, prevention, and treatment.⁹ Early prevention strategies that control
15 hypertension and hyperglycemia and identify patients with peripheral neuropathy or
16 peripheral vascular disease and annual screening for these conditions are strongly
17 recommended.⁹

1
2
3
4 1 *Cardiovascular diseases*
5

6
7 2 CVD is a leading cause of mortality in patients with type 1 diabetes^{63,64} and accounts for
8
9
10 3 the greatest proportion of healthcare spending for patients with diabetes.^{64,65} As compared to
11
12
13 4 patients without diabetes, type 1 diabetes increases the risk of CVD by ten fold,^{63,66} which
14
15
16 5 contributes to two-thirds of mortality in patients with type 1 diabetes.^{67,68} The Pittsburgh
17
18
19 6 EDC Study showed an incidence density of 3.6 per 1,000 person-years for coronary heart
20
21
22 7 diseases (defined as coronary-artery-disease-related death, a history of myocardial infarction,
23
24
25 8 angiographic stenosis $\geq 50\%$ including revascularization) over a period of 12 years,¹⁰ while
26
27
28 9 the present study found that the incidence density for a broader category of CVD (including
29
30
31 10 myocardial infarction, ischemic heart diseases, heart failure, stroke, and arrhythmia, as shown
32
33
34 11 in Supplementary Table 1) in the Taiwanese population with type 1 diabetes within 15 years
35
36
37 12 of follow-up was 4.39 per 1,000 person-years. The cumulative incidences of CVD (including
38
39
40 13 only stroke and coronary heart disease) at 12 years after diabetes was diagnosed was 1-2%
41
42
43 14 among Finnish type 1 diabetes patients,¹³ which is lower than that for the Taiwanese type 1
44
45
46 15 diabetes patients in the present study (~5.2%). Moreover, we found that late-onset patients
47
48
49 16 were greatly affected by CVD. In fact, old age is recognized as a predictor of vascular
50
51
52 17 diseases,⁶³ which may be explained by the calcification of extremity arteries and hypertension
53
54
55
56
57
58
59
60

1 in older age patients, which are risk factors of macrovascular diseases.⁶⁹

2 **Methodological concerns**

3 Some limitations of this study should be acknowledged. The classification of
4 diabetes-related complications based on the ICD-9 CM codes in claims data may
5 underestimate the occurrence of the complications. For example, patients experiencing
6 clinical symptoms/signs of diabetes-related complications (e.g., hypoglycemia) may not see
7 doctors if they can tolerate them. Also, the claims data do not capture clinical/minor
8 symptoms or signs of diabetes-related complications such as minor microalbuminuria. The
9 glycemic biomarkers such as blood glucose were not available from the claims data so the
10 identification of hyperglycemia or hypoglycemia was only based on the ICD-9 CM diagnosis
11 codes. So, we might under-estimate the incidence of hypoglycemic events and may not be
12 able to disentangle the severity of hypoglycemia. However, the claims records capture
13 defined diabetes-related complications that are required for medical assistance or treatments,
14 which lead to more conservative estimates and reveal important manifestations of
15 diabetes-related complications for clinical attention. Moreover, based on our operational
16 definition for hospitalized hypoglycemia (i.e., any one of diagnosis codes with hypoglycemia
17 from the five diagnosis codes in the inpatient files of the NHIRD), two types of

1 hypoglycemic events could be included: (1) hospital admission for hypoglycemia, and (2)
2 other reasons for hospital admission (e.g., DKA), and then hypoglycemia happened during
3 hospitalization. It is difficult to differentiate these two types of hypoglycemic events based on
4 the retrospective claims data we utilized. However, in the clinical practice in Taiwan, the first
5 code from the five diagnosis codes in hospitalization is typically to be the main/primary
6 reason for hospital admission. With this regard, we re-run the analyses for hospitalized
7 hypoglycemia which was identified from the first diagnosis code in hospitalization. The
8 results were provided in the Supplementary Table 2, and Supplementary Figures 2 and 3.
9 These re-analytical results may also ease the concern that patients who came to hospital
10 primarily for reasons that may induce hypoglycemia during hospitalization. Lastly, the
11 generalizability of our study results may be limited to ethnically Chinese populations. In
12 addition, our results may represent only ethnically Chinese patients with type 1 diabetes in
13 Taiwan.

14 **Conclusions**

15 Utilizing an incident cohort of type 1 diabetes patients diagnosed during the period
16 1999-2012 with a maximum of 15 years of follow-up, we found that most type 1 diabetes
17 patients were affected by DKA and retinopathy, which highlight the critical need to identify

1 precipitating causes and modifiable factors for developing preventive strategies and
2 intervening treatment protocols to minimize the impact of these complications. Age and sex
3 discrepancies appear in epidemiological data of diabetes-related complications; late-onset
4 diabetes females were greatly affected by advanced retinopathy (i.e., STDR) and hospitalized
5 hypoglycemia, while early-onset females had a high incidence of DKA. Chronic
6 diabetes-related complications were more common in late-onset type 1 diabetes patients,
7 while early-onset individuals were most affected by acute complications. More attention
8 should be given to identify potential risk factors and contributors to such age-sex differences
9 in diabetes-related complications. Population-based data on the incidence of diabetes-related
10 complications from this study are important for clinicians to recognize the need for diagnostic
11 awareness and for policy-makers to develop effective treatments for patients with type 1
12 diabetes.

13

1
2
3
4 1 **Acknowledgments:** We gratefully thank National Cheng Kung University and its affiliated
5
6
7 2 hospital for all their support.
8
9
10 3

11
12
13 4 **Funding:** This research was supported by the Ministry of Science and Technology, Taiwan,
14
15
16 5 grant MOST 104-2320-B-006-008-MY3.
17
18
19 6

20
21
22 7 **Competing interests:** No declared.
23
24
25 8

26
27
28 9 **Authors' contribution:** H.T.O. contributed substantially to the study concept and design,
29
30 10 acquisition of data, analysis and interpretation of data. T.Y.L. contributed to data collection
31
32 11 and the analysis. C.Y.L., J.S.W., and Z.J.S. provided statistical and clinical interpretation of
33
34 12 the results. H.T.O. wrote the first draft of the manuscript, and T.Y.L., C.Y.L., J.S.W., and
35
36 13 Z.J.S. very critically revised the manuscript. All authors gave approval for the publication of
37
38 14 the final version.
39
40 15

41 16 **Data sharing statement:** There are no additional data available in relation to this
42
43 17 manuscript.
44
45 18

References

1. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of Type I diabetes—the analysis of the data on published incidence trends. *Diabetologia* 1999;42(12):1395-1403.
2. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. *Diabetes care* 2000;23(10):1516-1526.
3. Soltesz G, Patterson CC, Dahlquist G. Worldwide childhood type 1 diabetes incidence—what can we learn from epidemiology? *Pediatric diabetes* 2007;8(s6):6-14.
4. Lu CL, Shen HN, Chen HF, Li CY. Epidemiology of childhood Type 1 diabetes in Taiwan, 2003 to 2008. *Diabetic Medicine* 2014;31(6):666-673.
5. Goldstein DE, Walker B, Rawlings SS, Hess RL, England JD, Peth SB, Hewett JE. Hemoglobin A1c levels in children and adolescents with diabetes mellitus. *Diabetes Care* 1980;3(4):503-507.
6. Ziegler R, Heidtmann B, Hilgard D, Hofer S, Rosenbauer J, Holl R. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. *Pediatric diabetes* 2011;12(1):11-17.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *New England Journal of Medicine* 1993;329(20):1456-1462.
8. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-Cause Mortality Trends in a Large Population-Based Cohort With Long-Standing Childhood-Onset Type 1 Diabetes The Allegheny County Type 1 Diabetes Registry. *Diabetes care* 2010;33(12):2573-2579.
9. Bate KL, Jerums G. 3: Preventing complications of diabetes. *Medical journal of Australia* 2003;179(9):498-505.
10. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-Year Natural History of Type 1 Diabetes Complications The Pittsburgh Epidemiology of Diabetes Complications Study Experience. *Diabetes* 2006;55(5):1463-1469.
11. Stephenson J, Fuller JH, Group EICS. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. *Diabetologia* 1994;37(3):278-285.
12. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemc threshold.

1
2
3 *Kidney international* 2001;60(1):219-227.

- 4 13. Tuomilehto J, Borch-Johnsen K, Molarius A, Forsen T, Rastenyte D, Sarti C,
5 Reunanen A. Incidence of cardiovascular disease in Type 1 (insulin-dependent)
6 diabetic subjects with and without diabetic nephropathy in Finland. *Diabetologia*
7 1998;41(7):784-790.
- 8 14. Hovind P, Tarnow L, Rossing P, Graae M, Torp I, Binder C, Parving H-H.
9 Predictors for the development of microalbuminuria and macroalbuminuria in patients
10 with type 1 diabetes: inception cohort study. *Bmj* 2004;328(7448):1105.
- 11 15. Malik MO, Govan L, Petrie JR, Ghouri N, Leese G, Fischbacher C, Colhoun H,
12 Philip S, Wild S, McCrimmon R. Ethnicity and risk of cardiovascular disease (CVD):
13 4.8 year follow-up of patients with type 2 diabetes living in Scotland. *Diabetologia*
14 2015;58(4):716-725.
- 15 16. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic
16 complications. *Current diabetes reports* 2013;13(6):814-823.
- 17 17. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage
18 Renal Disease in the United States, National Institutes of Health, National Institute of
19 Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003.
- 20 18. Young BA, Katon WJ, Von Korff M, Simon GE, Lin EHB, Ciechanowski PS,
21 Bush T, Oliver M, Ludman EJ, Boyko EJ. Racial and ethnic differences in
22 microalbuminuria prevalence in a diabetes population: the pathways study. *Journal of*
23 *the American Society of Nephrology* 2005;16(1):219-228.
- 24 19. Lin W-H, Wang M-C, Wang W-M, Yang D-C, Lam C-F, Roan J-N, Li C-Y.
25 Incidence of and Mortality from Type I Diabetes in Taiwan From 1999 through 2010:
26 A Nationwide Cohort Study. *PloS one* 2014;9(1):e86172.
- 27 20. Cheng T-M. Taiwan's new national health insurance program: genesis and
28 experience so far. *Health Affairs* 2003;22(3):61-76.
- 29 21. Ou H-T, Chang K-C, Li C-Y, Wu J-S. Risks of cardiovascular diseases associated
30 with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with
31 type 2 diabetes: a nation-wide longitudinal study. *Cardiovascular diabetology*
32 2016;15(1):41.
- 33 22. Ou HT, Chang KC, Liu YM, Wu JS. Recent trends in the use of antidiabetic
34 medications from 2008 to 2013: A nation-wide population-based study from Taiwan.
35 *Journal of diabetes* 2016.
- 36 23. Hou W-H, Chang K-C, Li C-Y, Ou H-T. Dipeptidyl peptidase-4 inhibitor use is
37 not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 population-based cohort study. *Pain* 2016;157(9):1954-1959.
- 4 24. Ou H-T, Yang C-Y, Wang J-D, Hwang J-S, Wu J-S. Life Expectancy and
5 Lifetime Health Care Expenditures for Type 1 Diabetes: A Nationwide Longitudinal
6 Cohort of Incident Cases Followed for 14 Years. *Value in Health* 2016;19(8):976-984.
- 7 25. Ou HT, Chang KC, Li CY, Wu JS. Comparative cardiovascular risks of
8 dipeptidyl peptidase-4 inhibitors with other 2nd and 3rd line antidiabetic drugs in
9 patients with type 2 diabetes. *British Journal of Clinical Pharmacology* 2017.
- 10 26. Ou H-T, Chen Y-T, Liu Y-M, Wu J-S. Comparative cost-effectiveness of
11 metformin-based dual therapies associated with risk of cardiovascular diseases among
12 Chinese patients with type 2 diabetes: Evidence from a population-based national
13 cohort in Taiwan. *Diabetes Research and Clinical Practice* 2016;116:14-25.
- 14 27. Vella S, Buetow L, Royle P, Livingstone S, Colhoun H, Petrie J. The use of
15 metformin in type 1 diabetes: a systematic review of efficacy. *Diabetologia*
16 2010;53(5):809-820.
- 17 28. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with
18 type 1 diabetes. *Diabetes Care* 2005;28(7):1562-1567.
- 19 29. Gail MH, Benichou J. *Encyclopedia of epidemiologic methods*: John Wiley &
20 Sons; 2000.
- 21 30. Sahai H, Khurshid A. *Statistics in epidemiology: methods, techniques and*
22 *applications*: CRC press; 1995.
- 23 31. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a
24 competing risk. *The Annals of statistics* 1988:1141-1154.
- 25 32. Graves EJ, Gillum BS. Detailed diagnoses and procedures, National Hospital
26 Discharge Survey, 1995. *Vital Health Stat 13* 1997(130):1-146.
- 27 33. Javor KA, Kotsanos JG, McDonald RC, Baron AD, Kesterson JG, Tierney WM.
28 Diabetic ketoacidosis charges relative to medical charges of adult patients with type I
29 diabetes. *Diabetes Care* 1997;20(3):349-354.
- 30 34. Rewers A, Chase HP, Mackenzie T, Walravens P, Roback M, Rewers M,
31 Hamman RF, Klingensmith G. Predictors of acute complications in children with type
32 1 diabetes. *Jama* 2002;287(19):2511-2518.
- 33 35. Neu A, Willasch A, Ehehalt S, Hub R, Ranke MB. Ketoacidosis at onset of type
34 1 diabetes mellitus in children—frequency and clinical presentation. *Pediatric diabetes*
35 2003;4(2):77-81.
- 36 36. Alaghebandan R, Collins KD, Newhook LA, MacDonald D. Childhood type 1
37 diabetes mellitus in Newfoundland and Labrador, Canada. *Diabetes research and*

- 1
2
3 *clinical practice* 2006;74(1):82-89.
- 4 37. Meltzer LJ, Johnson SB, Prine JM, Banks RA, Desrosiers PM, Silverstein JH.
5 Disordered eating, body mass, and glycemic control in adolescents with type 1
6 diabetes. *Diabetes care* 2001;24(4):678-682.
- 7
8 38. Rodin GM, Daneman D. Eating disorders and IDDM: a problematic association.
9 *Diabetes Care* 1992;15(10):1402-1412.
- 10
11 39. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic
12 hypoglycaemia in 411 type 1 diabetic patients. *Diabetic Medicine* 1991;8(3):217-222.
- 13
14 40. Craig ME, Jones TW, Silink M, Ping YJ, International Diabetes Federation
15 Western Pacific Region Steering C. Diabetes care, glycemic control, and
16 complications in children with type 1 diabetes from Asia and the Western Pacific
17 Region. *Journal of Diabetes and its Complications* 2007;21(5):280-287.
- 18
19 41. Aye T, Reiss AL, Kesler S, Hoang S, Drobny J, Park Y, Schleifer K, Baumgartner
20 H, Wilson DM, Buckingham BA. The feasibility of detecting neuropsychologic and
21 neuroanatomic effects of type 1 diabetes in young children. *Diabetes care*
22 2011;34(7):1458-1462.
- 23
24 42. Northam EA, Anderson PJ, Jacobs R, Hughes M, Warne GL, Werther GA.
25 Neuropsychological profiles of children with type 1 diabetes 6 years after disease
26 onset. *Diabetes care* 2001;24(9):1541-1546.
- 27
28 43. Ho MS, Weller NJ, Ives FJ, Carne CL, Murray K, vanden Driesen RI, Nguyen
29 TP, Robins PD, Bulsara M, Davis EA. Prevalence of structural central nervous system
30 abnormalities in early-onset type 1 diabetes mellitus. *The Journal of pediatrics*
31 2008;153(3):385-390.
- 32
33 44. Umpierrez GE, Murphy MB, Kitabchi AE. Diabetic ketoacidosis and
34 hyperglycemic hyperosmolar syndrome. *Diabetes Spectrum* 2002;15(1):28-36.
- 35
36 45. VanNewkirk MR, Weih L, McCarty CA, Taylor HR. Cause-specific prevalence
37 of bilateral visual impairment in Victoria, Australia: the Visual Impairment Project.
38 *Ophthalmology* 2001;108(5):960-967.
- 39
40 46. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD,
41 Ferris FL, 3rd, Klein R, American Diabetes A. Diabetic retinopathy. *Diabetes Care*
42 2003;26 Suppl 1:S99-S102.
- 43
44 47. Lin J-C, Shau W-Y, Lai M-S. Sex-and age-specific prevalence and incidence
45 rates of sight-threatening diabetic retinopathy in Taiwan. *JAMA ophthalmology*
46 2014;132(8):922-928.
- 47
48 48. Monti MC, Lonsdale JT, Montomoli C, Montross R, Schlag E, Greenberg DA.

- 1
2
3 Familial risk factors for microvascular complications and differential male-female
4 risk in a large cohort of American families with type 1 diabetes. *The Journal of*
5 *Clinical Endocrinology & Metabolism* 2007;92(12):4650-4655.
- 6
7
8 49. Minuto N, Emmanuele V, Vannati M, Russo C, Rebora C, Panarello S, Pistorio A,
9 Lorini R, d'Annunzio G. Retinopathy screening in patients with type 1 diabetes
10 diagnosed in young age using a non-mydriatic digital stereoscopic retinal imaging.
11 *Journal of endocrinological investigation* 2012;35(4):389-394.
- 12
13
14 50. Holl R, Lang G, Grabert M, Heinze E, Lang G, Debatin K. Diabetic retinopathy
15 in pediatric patients with type-1 diabetes: effect of diabetes duration, prepubertal and
16 pubertal onset of diabetes, and metabolic control. *The Journal of pediatrics*
17 1998;132(5):790-794.
- 18
19
20 51. Hletala K, Harjutsalo V, Forsblom C, Groop P-H, Group fs. Age at onset and the
21 risk of proliferative retinopathy in type 1 diabetes. *Diabetes care*
22 2010;33(6):1315-1319.
- 23
24
25 52. Marshall SM. Clinical features and management of diabetic nephropathy.
26 *Textbook of diabetes Boston: Blackwell Publishing* 2003;2003.
- 27
28
29 53. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of
30 severe retinopathy and persisting decrease of nephropathy in an unselected population
31 of Type 1 diabetes—the Linköping Diabetes Complications Study. *Diabetologia*
32 2004;47(7):1266-1272.
- 33
34
35 54. Donaghue KC, Fairchild JM, Craig ME, Chan AK, Hing S, Cutler LR, Howard
36 NJ, Silink M. Do all prepubertal years of diabetes duration contribute equally to
37 diabetes complications? *Diabetes care* 2003;26(4):1224-1229.
- 38
39
40 55. Svensson M, Nyström L, Schön S, Dahlquist G. Age at Onset of
41 Childhood-Onset Type 1 Diabetes and the Development of End-Stage Renal Disease
42 A nationwide population-based study. *Diabetes Care* 2006;29(3):538-542.
- 43
44
45 56. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, Holl RW.
46 Diabetic Nephropathy in 27,805 Children, Adolescents, and Adults With Type 1
47 Diabetes Effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset,
48 and sex. *Diabetes care* 2007;30(10):2523-2528.
- 49
50
51 57. International Comparisons. *American Journal of Kidney*
52 *Diseases*;57(1):e383-e396.
- 53
54
55 58. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT,
56 Klein RL, dcct/edic Research G. Lipoproteins in the DCCT/EDIC cohort: associations
57 with diabetic nephropathy. *Kidney international* 2003;64(3):817-828.

- 1
2
3 59. Rossing P, Hougaard P, Parving H-H. Risk Factors for Development of Incipient
4 and Overt Diabetic Nephropathy in Type 1 Diabetic Patients A 10-year prospective
5 observational study. *Diabetes care* 2002;25(5):859-864.
6
7
8 60. American Diabetes A. Standards of medical care for patients with diabetes
9 mellitus. *Puerto Rico Health Sciences Journal* 2013;20(2).
10
11 61. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA,
12 Maser RE, Sosenko JM, Ziegler D. Diabetic neuropathies a statement by the
13 American Diabetes Association. *Diabetes care* 2005;28(4):956-962.
14
15 62. Veglio M, Sivieri R. Prevalence of neuropathy in IDDM patients in Piemonte,
16 Italy. *Diabetes care* 1993;16(2):456-461.
17
18 63. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W,
19 Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients
20 with insulin-treated diabetes. *Diabetologia* 2003;46(6):760-765.
21
22 64. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS. The Effect of
23 Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes The Diabetes
24 Control and Complications Trial/Epidemiology of Diabetes Interventions and
25 Complications Study. *Diabetes care* 2007;30(8):2107-2112.
26
27 65. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002.
28 *Diabetes care* 2003;26(3):917.
29
30 66. Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK,
31 Becker DJ, Cavender DE, Drash AL. The Pittsburgh insulin-dependent diabetes
32 mellitus (IDDM) morbidity and mortality study: mortality results. *Diabetes*
33 1984;33(3):271-276.
34
35 67. Borch-Johnsen K, Nissen H, Henriksen E, Kreiner S, Salling N, Deckert T,
36 Nerup J. The Natural History of Insulin-Dependent Diabetes Mellitus in Denmark: 1.
37 Long-term survival with and without late diabetic complications. *Diabetic Medicine*
38 1987;4(3):201-210.
39
40 68. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing
41 natural history of nephropathy in type I diabetes. *The American journal of medicine*
42 1985;78(5):785-794.
43
44 69. Maser RE, Wolfson S, Ellis D, Stein EA, Drash AL, Becker DJ, Dorman JS,
45 Orchard TJ. Cardiovascular disease and arterial calcification in insulin-dependent
46 diabetes mellitus: interrelations and risk factor profiles. Pittsburgh Epidemiology of
47 Diabetes Complications Study-V. *Arteriosclerosis, Thrombosis, and Vascular Biology*
48 1991;11(4):958-965.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Overall incidence density of diabetes-related complications among patients with type 1 diabetes between 1999 and 2013

	Retinopathy	Proliferative retinopathy	STDR	Neuropathy	Nephropathy	Renal failure	CVD	DKA	Outpatient hypoglycemia	Hospitalized hypoglycemia
No. of cases*	3,359	3,970	3,983	3,742	3,634	4,003	3,916	2,205	3,934	3,987
No. of cases with event**	1,532	157	90	558	688	36	117	996	913	105
Follow-up time (person-years)†	15,675	26,733	27,139	23,320	21,936	27,491	26,664	8,224	22,865	26,968
Incidence density (1,000 person-years) (95% CI)	97.74 (92.9-102.8)	5.87 (5.0-6.9)	3.32 (2.7-4.1)	23.93 (22.0-26.0)	31.36 (29.1-33.8)	1.31 (0.9-1.8)	4.39 (3.6-5.3)	121.11 (113.7-128.9)	39.93 (37.4-42.6)	3.89 (3.2-4.7)

* No. of cases refers to the number of patients who had no complication of interest in the baseline year (one year before diagnosis date).

** No. of cases with event refers to the number of patients who had incident events after type 1 diabetes was confirmed.

† Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.

Note: Patients with type 1 diabetes were retrieved from incidence cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrollment from Taiwan's National Health Insurance Program, or the end of 2013, whichever came first.

Abbreviations: STDR: sight-threatening diabetic retinopathy, CVD: cardiovascular disease, DKA: diabetic ketoacidosis, CI: confidence interval.

Table 2: Incidence density of diabetes-related complications by age and sex among patients with type 1 diabetes between 1999 and 2013

	Retinopathy	Proliferative retinopathy	STDR	Neuropathy	Nephropathy	Renal failure	CVD	DKA	Outpatient hypoglycemia	Hospitalized hypoglycemia
Male										
No. of cases*										
All male	1,618	1,886	1,892	1,778	1,695	1,901	1859	1,073	1,872	1,902
Early-onset (0-12 years)	654	719	719	714	700	719	712	396	718	719
Late-onset (≥ 13 years)	964	1,167	1,173	1,064	995	1,182	1,147	677	1,154	1,183
No. of cases with event**										
All male	693	64	34	261	332	15	60	447	452	28
Early onset	305	14	1	37	86	1	7	239	202	11
Late onset	388	50	33	224	246	14	53	208	250	17
Follow-up time (person-years)†										
All male	7,813	12,908	13,102	11,345	10,403	13,248	12,798	4,322	11,025	13,115
Early-onset	3,333	5,290	5,368	5,180	4,817	5,358	5,280	1,317	4,277	5,297
Late-onset	4,480	7,618	7,734	6,165	5,586	7,891	7,518	3,005	6,749	7,818
Incidence density (1,000 person-years) (95% CI)										
All male	88.70 (82.2-95.6)	4.96 (3.8-6.3)	2.60 (1.8-3.6)	23.01 (20.3-26.0)	31.91 (28.6-35.5)	1.13 (0.6-1.9)	4.69 (3.6-6.0)	103.43 (94.1-113.5)	41.00 (37.3-45.0)	2.13 (1.4-3.1)
Early-onset	91.52	2.65	0.19	7.14	17.85	0.19	1.33	181.53	47.23	2.08
										33

1											
2		(81.5-102.4)	(1.4-4.4)	(0.0-1.0)	(5.0-9.8)	(14.3-22.0)	(0.0-1.0)	(0.5-2.7)	(159.2-206.1)	(40.9-54.2)	(1.0-3.7)
3											
4	Late-onset	86.60	6.56	4.27	36.34	44.04	1.77	7.05	69.22	37.05	2.17
5											
6		(78.2-95.7)	(4.9-8.7)	(2.9-6.0)	(31.7-41.4)	(38.7-49.9)	(1.0-3.0)	(5.3-9.2)	(60.1-79.3)	(32.6-41.9)	(1.3-3.5)
7	95% CI of incidence density										
8	difference for male, early vs.	-8.5 to 18.3	-6.4 to -1.4‡	-5.9 to -2.3‡	-34.8 to -23.6‡	-33.1 to -19.3‡	-2.8 to -0.4‡	-8.1 to -3.3‡	91.5 to 133.1‡	2.4 to 17.9‡	-1.7 to 1.5
9	late-onset										
10											
11											
12	Female										
13											
14	No. of cases*										
15											
16	All female	1,741	2,084	2,091	1,964	1,939	2,102	2,057	1,132	2,062	2,085
17											
18	Early-onset	721	777	777	772	764	777	773	413	774	774
19											
20	Late-onset	1,020	1,307	1,314	1,192	1,175	1,325	1,284	719	1,288	1,311
21	No. of cases with event**										
22											
23	All female	839	93	56	297	356	21	57	549	461	77
24											
25	Early-onset	358	18	6	50	109	1	11	277	229	21
26											
27	Late-onset	481	75	50	247	247	20	46	272	232	56
28	Follow-up time (person-years)†										
29											
30	All female	7,862	13,825	14,037	11,976	11,533	14,243	13,866	3,902	11,840	13,853
31											
32	Early-onset	3,616	5,848	5,910	5,610	5,283	5,927	5,871	1,183	4,642	5,777
33											
34	Late-onset	4,246	7,977	8,127	6,365	6,250	8,317	7,995	2,719	7,199	8,076
35	Incidence density										
36											
37	(1,000 person-years)										
38	(95% CI)										
39											

1											
2											
3	All female	106.72	6.73	3.99	24.80	30.87	1.47	4.11	140.69	38.94	5.56
4		(99.6-114.2)	(5.4-8.2)	(3.0-5.2)	(22.1-27.8)	(27.7-34.2)	(0.9-2.3)	(3.1-5.3)	(129.2-153.0)	(35.5-42.7)	(4.4-6.9)
5											
6	Early-onset	99.01	3.08	1.02	8.91	20.63	0.17	1.87	234.05	49.34	3.63
7		(89.0-109.8)	(1.8-4.9)	(0.4-2.2)	(6.6-11.8)	(16.9-24.9)	(0.0-0.9)	(0.9-3.4)	(207.3-263.3)	(43.1-56.2)	(2.3-5.6)
8											
9	Late-onset	113.29	9.40	6.15	38.80	39.52	2.40	5.75	100.05	32.23	6.93
10		(103.4-123.9)	(7.4-11.8)	(4.6-8.1)	(34.1-44.0)	(34.7-44.8)	(1.5-3.7)	(4.2-7.7)	(88.5-112.7)	(28.2-36.7)	(5.2-9.0)
11											
12	95% CI of incidence density										
13	difference for female, early vs.	-28.8 to 0.2	-9.1 to -3.6‡	-7.3 to -3.0‡	-35.5 to -24.2‡	-25.3 to -12.5‡	-3.5 to -1.0‡	-6.0 to -1.7‡	108.4 to 159.6‡	9.8 to 24.4‡	-5.8 to -0.8‡
14	late-onset										
15											
16	95% CI of incidence density										
17	difference for male vs. female	-27.8 to -8.2‡	-3.6 to 0.1	-2.8 to -0.02‡	-5.8 to 2.2	-3.6 to 5.7	-1.2 to 0.5	-1.0 to 2.2	-52.3 to -22.2‡	-3.1 to 7.2	-4.9 to -1.9‡
18											
19											

* No. of cases refers to the number of patients who had no complication of interest in the baseline year (one year before diagnosis date).

** No. of cases with event refers to the number of patients who had incident events after type 1 diabetes was confirmed.

† Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.

Note: Patients with type 1 diabetes were retrieved from incidence cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrollment from Taiwan's National Health Insurance Program, or the end of 2013, whichever came first.

Abbreviations: STDR: sight-threatening diabetic retinopathy, CVD: cardiovascular disease, DKA: diabetic ketoacidosis, CI: confidence interval. ‡ $p < 0.05$

1 **Figure 1. Flowchart of study cohort selection**

2
3 **Figure 2: Cumulative incidences of diabetic ketoacidosis, mild hypoglycemia according to the**
4 **duration of diabetes in patients with type 1 diabetes (shadow area indicates 95 % confidence interval)**

5
6
7
8 **Figure 3: Cumulative incidences of retinopathy, sight-threatening diabetic retinopathy, neuropathy,**
9 **nephropathy, renal failure, and cardiovascular diseases according to the duration of diabetes in**
10 **patients with type 1 diabetes (shadow area indicates 95 % confidence interval)**

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flowchart of study cohort selection

209x148mm (300 x 300 DPI)

new only




Figure 2: Cumulative incidences of diabetic ketoacidosis, mild hypoglycemia according to the duration of diabetes in patients with type 1 diabetes (shadow area indicates 95 % confidence interval)

209x148mm (300 x 300 DPI)

new only




Figure 3: Cumulative incidences of retinopathy, sight-threatening diabetic retinopathy, neuropathy, nephropathy, renal failure, and cardiovascular diseases according to the duration of diabetes in patients with type 1 diabetes (shadow area indicates 95 % confidence interval)

297x420mm (300 x 300 DPI)

Supplementary Table 1: Diabetes-related acute and chronic complications

Complications	ICD-9-CM disease codes	ICD-9-CM procedure codes	NHI procedure codes
CVD (cardiovascular disease and cerebrovascular disease)^{a,b}			
Acute myocardial infarction	410, 412*	---	---
Ischemic heart disease	411, 413, 414, V45.81, V45.82	00.66, 36.0, 36.1, 36.2, 36.3, 36.9, 88.5	---
Heart failure	428	---	---
Stroke	430-437, 438*, V12.54	00.61, 00.63, 38.11, 38.12	---
Cardiogenic shock	785.51	---	---
Sudden cardiac arrest	V12.53	---	---
Arteriosclerotic cardiovascular disease	429.2	---	---
Arrhythmia	426, 427	---	---
Microvascular complications^{a,c}			
Nephropathy	250.4, 403, 404, 580, 581, 582, 583, 584, 585, 586, 587, 588, 593, 791.0, V13.03, V42.0, V45.1, V56	38.95, 39.27, 39.42, 39.95, 54.98, 55.4, 55.5, 55.6	---
Renal failure (dialysis or transplantation) ^d	V45.1, V56	39.95, 54.98 55.6	---
Retinopathy	250.5, 361, 362, 364, 365, 366, 368, 369, 377, 379.2	12.41, 12.73, 14.23, 14.24, 14.25, 14.33, 14.34, 14.35, 14.53, 14.54, 14.55, 16.92, 16.99	86206B, 86207B, 60001C, 60002C*, 60003C, 60004C*
Proliferative retinopathy ^d	362.02	---	60001C, 60002C*, 60003C, 60004C*
Sight-threatening diabetic retinopathy ^e	---	---	86206B, 86207B, 60001C, 60002C*, 60003C, 60004C*
Neuropathy	250.6, 302.72, 337.1, 354, 355, 357.2, 358.1, 607.84, 713.5, 729.2	---	---
Metabolic complications			
Diabetic ketoacidosis ^a	250.1	---	---
Hypoglycemia ^{a,f}	251.0, 251.1, 251.2, 270.3, 775.0, 775.6	---	---

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

*For identifying prevalent cases only. a: Nutr Metab Cardiovasc Dis. 2014;24(1):10-7. b: Pharmacoepidemiol Drug Saf. 2009;18(6):497-503. c: Diabetes Care. 2008;31(3):596-615. d: Diabetes. 2006;55(5):1463-9. e: JAMA Ophthalmol. 2014;132(8):922-928. f: BMC Endocr Disord. 2008;8:4. Abbreviations: ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification, NHI: Taiwan National Health Insurance.

For peer review only

Supplementary Table 2: Incidence density of hospitalized hypoglycemia among patients with incident type 1 diabetes diagnosed between 1999 and 2013 (using primary diagnosis to define hospitalization for hypoglycemia)

	Overall patients	Male subgroup			Female subgroup		
		Overall male [‡]	Male early-onset (0-12 years) [‡]	Male late-onset (≥13 years)	Overall female	Female early-onset (0-12 years) [‡]	Female late-onset (≥13 years)
No. of cases*	4,001	1,903	719	1,184	2,098	777	1,321
No. of cases with event	36	12	4	8	24	6	18
Follow-up time (person-years)†	27,374	13,205	5,327	7,878	14,169	5,890	8,280
Incidence density (1,000 person-years)	1.32	0.91	0.75	1.02	1.69	1.02	2.17
(95% CI)	(0.9-1.8)	(0.5-1.6)	(0.2-1.9)	(0.4-2.0)	(1.1-2.5)	(0.4-2.2)	(1.3-3.4)

* No. of cases refers to the number of patients who had no complication event of interest before type 1 diabetes was confirmed.


† Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.



Note: Patients with type 1 diabetes were retrieved from incidence cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrollment from Taiwan's National Health Insurance Program, or the end of 2013, whichever came first.

[‡] 95% CI of incidence density difference for male vs. female was [-1.6 to 0.1]; in male subgroup, early vs. late-onset was [-1.3 to 0.8]; and in female subgroup, early vs. late-onset was [-2.5 to 0.2].

Abbreviations: STDR: sight-threatening diabetic retinopathy, CVD: cardiovascular disease, DKA: diabetic ketoacidosis, CI: confidence interval.


Supplementary Figure 1: Age-sex-specific cumulative incidences of diabetes complications according to duration of diabetes in patients with type 1 diabetes (early-onset: 0-12 years, late-onset: ≥ 13 years)








1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



Nephropathy



Renal failure







Note:
 p value for comparison of cumulative incidence of retinopathy for male vs. female was 0.0006, for male, early vs. late-onset was 0.4553, for female, early vs. late-onset was 0.0908.
 p value for comparison of cumulative incidence of proliferative retinopathy for male vs. female was 0.0567, for male, early vs. late-onset was 0.0013, for female, early vs. late-onset was <.0001.

1 *p* value for comparison of cumulative incidence of sight-threatening diabetic retinopathy for male vs. female was 0.0405, for male, early vs. late-onset was
2 <.0001, for female, early vs. late-onset was <.0001.

3 *p* value for comparison of cumulative incidence of neuropathy for male vs. female was 0.4050, for male, early vs. late-onset was <.0001, for female, early vs.
4 late-onset was <.0001.

5 *p* value for comparison of cumulative incidence of nephropathy for male vs. female was 0.6191, for male, early vs. late-onset was <.0001, for female, early vs.
6 late-onset was <.0001.

7 *p* value for comparison of cumulative incidence of renal failure for male vs. female was 0.4222, for male, early vs. late-onset was 0.0078, for female, early vs.
8 late-onset was 0.0003.


9 *p* value for comparison of cumulative incidence of cardiovascular disease for male vs. female was 0.4655, for male, early vs. late-onset was <.0001, for female,
10 early vs. late-onset was 0.0004.

11 *p* value for comparison of cumulative incidence of diabetic ketoacidosis for male vs. female was 0.0015, for male, early vs. late-onset was <.0001, for female,
12 early vs. late-onset was <.0001.

13 *p* value for comparison of cumulative incidence of outpatient hypoglycemia for male vs. female was 0.4095 for male, early vs. late-onset was 0.0097, for
14 female, early vs. late-onset was <.0001.


15 *p* value for comparison of cumulative incidence of hospitalized hypoglycemia for male vs. female was <.0001, for male, early vs. late-onset was 0.9600, for
16 female, early vs. late-onset was 0.0113.

Supplementary Figure 2: Cumulative incidence of hospitalized for hypoglycemia according to the duration of diabetes in patients with type 1 diabetes (shadow area indicates 95 % confidence interval)



Only

Supplementary Figure 3: Age-sex-specific cumulative incidences of hospitalized for hypoglycemia according to duration of diabetes in patients with type 1 diabetes (early-onset: 0-12 years, late-onset: ≥ 13 years)



Note:

p value for comparison of cumulative incidence for male vs. female was 0.0782, for male, early vs. late-onset was 0.6272, for female, early vs. late-onset was 0.1326.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page number
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2, 3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7, 8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	7, 8
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8, 9
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	Not applicable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9, 10
		(c) Explain how missing data were addressed	9, 10
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	9
		(e) Describe any sensitivity analyses	9, 10

Continued on next page

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	8
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10, 11
		(b) Report category boundaries when continuous variables were categorized	10, 11
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	11

Discussion

Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	21
Generalisability	21	Discuss the generalisability (external validity) of the study results	21

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23
---------	----	---------------------------------------------------------------------------------------------------------------------------------------------------------------	----

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.